Product Number |
Description |
00/410 |
MAPREC assay of poliovirus type 1 (Sabin).100% 480-A, 525-C DNA(1st International Reference Preparation) |
00/416 |
Low Mutant Virus Reference for MAPREC assay of poliovirus type 1 (Sabin)(1st International Reference Preparation) |
00/418 |
MAPREC assay of poliovirus type 1 (Sabin) (1st International Standard) |
00/422 |
High Mutant Virus Reference for MAPREC assay of poliovirus type 1 (Sabin)(1st International Reference Preparation) |
00/440 |
Influenza Antiserum A/Singapore/1/57 (H2) |
00/442 |
Influenza anti B/Yamanashi/166/98 Serum |
00/498 |
Diphtheria Antitoxin Human IgG |
00/500 |
Botulinum Type A-E Antitoxin, Human Serum |
00/542 |
Influenza anti- A/Chick/Scotland/59 (H5N1) Serum |
00/546 |
Influenza Antigen B/Johannesburg/5/99 |
00/552 |
Influenza Antigen A/Duck/Singapore-Q/F119-3/97 (H5N3) |
00/556 |
Influenza anti-B/Johannesburg/5/99/ Serum |
00/572 |
Interferon Beta (Human, rDNA, Glycosylated) (3rd International standard) |
00/574 |
Interferon Beta SER17 Mutein (Human, rDNA derived) |
00/576 |
Interferon Beta (Human, Fibroblast-derived, Glycosylated) |
007SP |
Human Anti-Pneumococcal capsule Reference Serum (1st International Standard) |
01/412 |
Anti-Meningococcal Immunotype L3,7,9 Monoclonal Antibody |
01/420 |
Interleukin-17 (Human rDNA derived)(WHO Reference Reagent) |
01/426 |
Meningococcal group Y polysaccharide |
01/450 |
Influenza anti B/Guangdong/120/2000 Serum |
01/452 |
Influenza anti A/Panama/2007/99 (H3N2) HA serum |
01/506 |
Botulinum type F antitoxin, equine |
01/508 |
Botulinum type C antitoxin, equine |
01/510 |
Botulinum Antitoxin Equine Type D |
01/512 |
Botulinum type G antitoxin, equine |
01/514 |
Anti-Meningococcal Serosubtype P1.7 Monoclonal Antibody |
01/538 |
Anti-Meningococcal Serosubtype P1.16 mAb |
01/546 |
Influenza Antigen B/Guangdong/120/2000 |
01/580 |
Thrombin, human(2nd International Standard) |
01/600 |
Anti-Toxoplasma IgG, Human(International Standard) |
01/602 |
Anti-Parvovirus B19, plasma, human(2nd International Standard) |
01/612 |
Influenza Virus infectious B/Hawaii/10/01 |
01/614 |
Influenza Antigen A/New Caledonia/20/99 |
02/102 |
Influenza anti A/Panama/2007/99 Serum |
02/144 |
Anti-Meningococcal Serosubtype P1.15 mAb |
02/148 |
Anti-Meningococcal Serosubtype P1.4 mAb |
02/178 |
Anti-Meningococcal Serosubtype P1.2 mAb |
02/180 |
Anti-Meningococcal Serotype P2.2a mAb |
02/182 |
Anti-Japanese Encephalitis Virus Plasma, Human |
02/184 |
Anti-Japanese Encephalitis (Anti-JE) Virus Negative Control Plasma, Human |
02/206 |
Factor XIII Plasma, Human (1st International Standard) |
02/210 |
HIV (antibody), 1st International Reference Panel |
02/226 |
IVIG negative control for use with IVIG + anti-D(WHO Reference Reagent) |
02/228 |
IVIG + anti-D for use with negative control IVIG(WHO Reference Reagent) |
02/230 |
Biotinylated Brad-5 (Bio-Brad-5) |
02/232 |
Tetanus Toxoid (Non-Adsorbed) |
02/286 |
Vascular Endothelial Growth Factor 165 (VEGF165)(recDNA, human sequence)(WHO Reference Reagent) |
02/294 |
Influenza Antiserum A/chick/Italy/1347/99 (H7N1) |
02/308 |
Anti-Meningococcal Serotype P3.4 mAb |
02/310 |
Anti-Meningococcal Serotype P3.15 mAb |
02/318 |
Botulinum Antitoxin Equine Type E |
02/320 |
Anti-Meningococcal Serosubtype P1.3 mAb |
02/336 |
Influenza Antigen A/New Caledonia/20/99 |
02/338 |
Influenza anti A/Panama/2007/99 Serum |
02/342 |
Protein C Plasma, Human(2nd International Standard) |
03/104 |
HTLV-1 (antibody) Monitor Sample |
03/110 |
Influenza anti B/Shangdong/9/97 Serum |
03/114 |
Anti-Meningococcal Serosubtype P1.1 mAb |
03/124 |
Thrombopoietin ( Human rDNA derived) |
03/142 |
Anti-Meningococcal Serosubtype P1.14 mAb |
03/148 |
Keratinocyte growth factor (KGF, FGF-7)(24-163)(1st WHO Reference Reagent) |
03/150 |
Keratinocyte Growth Factor (KGF,FGF-7)(1st WHO Reference Reagent) |
03/152 |
Anti-HPA-1a (International Standard) |
03/164 |
Anti-B minimum potency reference preparation(International Standard) |
03/178 |
Vitamin B12, Serum Folate and holoTC (International standard) |
03/182 |
Anti-Meningococcal Serotype P3.21 mAb |
03/188 |
Anti-A minimum potency reference preparation(International Standard) |
03/190 |
Anti-HPA-3a(minimum potency)(WHO Reference Reagent) |
03/192 |
Thyroid-Stimulating Hormone, Recombinant, Human, for Bioassay (1st International standard) |
03/200 |
Interleukin - 18 (Human rDNA derived)(WHO Reference Reagent) |
03/210 |
Anti-Meningiococcal Serosubtype P1.6 mAb |
03/212 |
Influenza anti A/Wyoming/03/03 Serum |
03/220 |
Influenza Antigen A/Wyoming/03/03 |
03/224 |
Anti-Meningococcal Serosubtype P1.10 mAb |
03/226 |
Anti-Meningococcal Serosubtype P1.5 mAb |
03/228 |
Protein S, Plasma, Human(2nd International Standard) |
03/236 |
Anti-Meningococcal Serosubtype P1.13 mAb |
03/242 |
Influenza anti A/Puerto Rico/8/34 (H1N1) HA Serum |
03/244 |
Influenza Antiserum A/chick/Germany/N/49 |
03/258 |
Influenza Antigen A/New Caledonia/20/99 (IVR-116) |
03/262 |
Hepatitis B Surface Antigen subtype adw2, genotype A (International Reference Panel) |
04/122 |
Anti-Meningococcal Serosubtype P1.12 mAb |
04/160 |
Influenza Virus infectious NYMC X-147 |
04/166 |
TNF-related Apoptosis-Inducing Ligand (trail), Human, rDNA-derived(1st WHO Reference Reagent) |
04/170 |
Influenza Virus infectious A/Wellington/1/2004 |
04/172 |
Influenza Virus infectious IVR-139 |
04/176 |
Plasmodium falciparum DNA for NAT Assays(1st International Standard) |
04/198 |
Anti-Meningococcal Serotype P3.1 mAb |
04/202 |
Influenza Antigen B/ Jiangsu/10/2003 |
04/224 |
Factor V Leiden, Human gDNA, 1st International Genetic Reference Panel 2004 |
04/228 |
Influenza anti B/ Neuraminidase Serum |
04/242 |
Influenza anti B/Jiangsu/10/2003 HA Serum |
04/246 |
Anti-Meningococcal Serogroup W-135 mAb |
04/248 |
Anti-Meningococcal Serosubtype P1.19 mAb |
04/252 |
Protein C Concentrate, Human(1st International Standard) |
04/260 |
Influenza anti A/New Caledonia/20/99 HA Serum |
04/262 |
Influenza anti A/New York/55/2004 HA Serum |
04/264 |
Influenza Antigen A/New York/55/2004 (H3N2) (NYMC X-157) |
05/102 |
Influenza Virus infectious NYMC BX-7 |
05/106 |
Anti-HPA-1a minimum potency reagent(2nd WHO Reference reagent) |
05/112 |
Low Molecular Weight Heparin for Molecular Weight Calibration (2nd International Standard). |
05/130 |
Prothrombin Mutation G20210A, Human gDNA(1st International Genetic Reference Panel 2005) |
05/134 |
Anti-human papillomavirus type 16 serum (1st International Standard) |
05/162 |
Alpha-1-Antitrypsin, plasma derived(1st International standard) |
05/190 |
Anti Meningococcal Serosubtype P1.9 Monoclonal Antibody |
05/192 |
Anti Meningococcal Serotype P2.2b Monoclonal Antibody |
05/234 |
Influenza Antigen A/Hiroshima/52/2005 (H3N2) (IVR-142) |
05/236 |
Influenza anti A/Wisconsin/67/2005 Serum |
05/252 |
Influenza anti B Neuraminidase Serum |
06/108 |
Influenza Virus infectious IVR-116 |
06/124 |
Monoclonal Antibody for Serotyping Bordetella pertussis Fimbrial Antigen 2 (1st International Standard) |
06/128 |
Monoclonal Antibody for Serotyping Bordetella pertussis Fimbrial Antigen 3 (1st International Standard) |
06/140 |
Pertussis Antiserum(human)1st IS-WHO international Standard. |
06/142 |
Pertussis Antiserum (Human) 1st WHO Reference Reagent |
06/164 |
Influenza Virus infectious 1 VR-142 |
06/166 |
Antithrombin Concentrate, Human (3rd International Standard) |
06/170 |
Influenza Antigen A/New Caledonia/20/99 |
06/192 |
Influenza anti A/turkey/Turkey/1/05 (NIBRG-23) HA serum(sheepSH465 & SH466) |
06/202 |
Human Papillomavirus (HPV) Type 16 DNA (1st International Standard) |
06/206 |
Human Papillomavirus (HPV) Type 18 DNA (1st International Standard) |
06/242 |
Influenza Virus Infectious NYMC X-161B (A/Wisconsin/67/2005 HGR) |
688 |
SARS CoV-1 spike S1 protein |
07/102 |
Influenza Antigen A/Solomon Islands/3/2006 (H1N1)(IVR-145) |
07/104 |
Influenza anti A/Solomon Islands/3/2006 (H1N1) (IVR-145) HA Serum |
07/112 |
Influenza Antigen A/turkey/Turkey/1/2005 (H5N1) NIBRG-23 |
07/132 |
Influenza Virus infectious B/Malaysia/2506/2004 |
07/144 |
Influenza Virus infectious IVR-145, |
07/146 |
Influenza anti A/HongKong/1073/99 like (H9) HA Serum (sheep) |
07/148 |
Influenza anti A/Vietnam/1194/04 (H5N1) HA Serum |
07/150 |
Human Plasma Anti-Influenza H5N1 (1st International Standard) |
07/164 |
Anti-hepatitis B surface antigen(Anti-HBs) immunoglobulin (2nd International Standard) |
07/184 |
Influenza anti B/Malaysia/2506/2004-HA Serum |
07/202 |
Recombinant soluble transferrin receptor (rsTfR)(1st WHO Reference Reagent) |
07/216 |
Diphtheria Toxoid (Adsorbed) (4th International Standard) |
07/222 |
RhD/SRY Plasma DNA sensitivity standard (1st WHO Reference Reagent) |
07/228 |
Blood Coagulation Factor VIIa, Concentrate, Human, 2nd International Standard” |
07/270 |
BCG Vaccine of Danish 1331 sub-strain (1st WHO Reference Reagent) |
07/272 |
BCG Vaccine of Tokyo 172 sub-strain(1st WHO Reference Reagent) |
07/274 |
BCG Vaccine of Russian BCG-I sub-strain(1st WHO Reference Reagent) |
07/278 |
Influenza anti A/mallard/Netherlands/12/2000 (H7) HA serum (NIBRG-60) (sheep SH474 AND SH475) |
07/286 |
Monitor sample for HBsAg 0.05IU/ml |
07/288 |
Hepatitis B Surface Antigen (HBsAg) British Working Standard 0.2 IU/ml |
07/290 |
Influenza Antigen A/Anhui/1/05 (H5N1) IBCDC-RG-6 |
07/296 |
Influenza Virus (A/Christchurch/1/2003, H1N1) for Nucleic Acid Amplification Techniques |
07/298 |
Influenza Virus (A/Wyoming/3/2003, H3N2) for Nucleic Acid Amplification Techniques |
07/300 |
Influenza Virus (B/Jiangsu/10/2003) for Nucleic Acid Amplification Techniques |
07/304 |
Anti-D for assuring operator and test performance |
07/306 |
Anti-A and anti-B in IVIG: Positive control for haemagglutination tests (WHO Reference Reagent) |
07/316 |
Blood Coagulation Factor VIII and Von Willebrand Factor in Plasma (6th I.S.) |
07/318 |
Meningococcal Group C Polysaccharide |
07/328 |
Unfractionated Heparin (6th I.S.) |
07/336 |
Influenza Antigen A/mallard/Netherlands/12/00(H7N3) NIBRG-60 |
07/338 |
Influenza antiserum A/Anhui/1/05 (H5) |
07/348 |
Influenza Virus infectious NYMC X-171B |
07/350 |
Blood Coagulation Factor VIII Concentrate (8th I.S.) |
07/358 |
Influenza Virus infectious NIB-50 |
07/362 |
Influenza Virus infectious IVR-149 |
07/B498 |
QCRHBclgMQC1-IgM Anti-HBc Quality Control Serum: Sample1 |
08/100 |
Influenza Antigen A/Brisbane/59/2007 (IVR-148) (H1N1) |
08/108 |
Influenza Virus Infectious NIBRG-91 (H9N2) |
08/118 |
Parainfluenza Virus serotype 3 for Nucleic Acid Amplification Techniques |
08/120 |
Human Respiratory syncytial virus A2 for Nucleic Acid Amplification Techniques |
08/126 |
Influenza Anti N1 Neuraminidase Serum SH485 |
08/138 |
Influenza Virus Infectious B/Florida/4/2006 |
08/140 |
Influenza Antigen B/Florida/4/2006 |
08/142 |
Influenza antiserum A/Anhui/1/05 (H5) |
08/148 |
HLA Class II Positive Control |
08/154 |
Influenza Virus Infectious NIBRG-12 (H5N1) |
08/156 |
Influenza Virus Infectious NIBRG-23 30060 VE3 (H5N1) |
08/158 |
Fragile X Syndrome gDNA (1st International Genetic Reference Panel) |
08/160 |
Haemophilia A, Intron-22 inversion, gDNA, (1st International Genetic Reference Panel) |
08/174 |
Human Coxsackie B4 for Nucleic Acid Amplification Techniques |
08/176 |
Parainfluenza Virus serotype 1 for Nucleic Acid Amplification Techniques |
08/178 |
Parainfluenza Virus serotype 2 for Nucleic Acid Amplification Techniques |
08/180 |
Parainfluenza virus serotype 4 for Nucleic Acid Amplification Techniques |
08/184 |
Influenza Antigen B/Malaysia/2506/2004 |
08/202 |
Influenza anti A/chick/Hong Kong/G9/1997/(H9) HA serum (NIBRG-94)(H9N1) |
08/204 |
Thyroid Stimulating Antibody (2nd I.S.) |
08/208 |
Influenza Antigen A/HongKong/1073/99 (H9N2) |
08/210 |
Influenza anti A/Cambodia/R0405050/2007 (H5) HA serum (NIBRG-86) |
08/214 |
Meningococcal Serogroup C polysaccharide (1st International Standard) |
08/216 |
Influenza Antigen A/Cambodia/RO405050/2007 (H5N1) |
08/218 |
Tetanus Toxoid Adsorbed (4th International Standard) |
08/228 |
Influenza Antigen A/chick/Hong Kong/G9/1997 (H9N2) NIBRG-91 |
08/230 |
Streptodornase (2nd International Standard) |
08/246 |
Influenza anti A/Brisbane/10/2007- like HA serum |
08/248 |
Influenza Virus Infectious NIBRG-107 VE2 30480 |
08/250 |
Influenza Virus Infectious NIBRG-63 VE2 30500 (H7N1) |
08/252 |
Influenza Virus Infectious NIBRG-109 VE2 30490 |
08/256 |
C1- Inhibitor, Concentrate (1st International Standard) |
08/258 |
Antithrombin, Plasma (3rd International Standard) |
08/262 |
C1 Inhibitor (Plasma)(1st International Standard) |
08/266 |
Sex Hormone Binding Globulin.(2nd International Standard) |
08/268 |
Influenza Antigen A/mallard/England/727/2006 (H2N3)NIBRG-107 |
08/278 |
Influenza Antigen A/Brisbane/10/2007-like (Prepared from A/Uruguay/716/2007 (NYMC X-175C)) |
08/298 |
Influenza Virus Infectious B/Brisbane/33/2008 30720 E5 |
08/300 |
Influenza Virus Infectious IVR-148 |
08/304 |
Influenza virus infectious NYMC X-175C |
08/318 |
Human Norovirus GI Working Reagent for Nucleic Acid Amplification Testing |
08/320 |
Human Metapneumovirus Working Reagent for Nucleic Acid Amplification Testing |
08/322 |
Human Parechovirus Working Reagent for Nucleic Acid Amplification Testing |
08/356 |
Influenza antiserum A/Japan/305/57 (H2) |
08/362 |
Influenza Antigen A/New York/107/2003 (H7N2)NIBRG-109 |
09/100 |
Influenza anti A/mallard/England/727/2006 (N3) NA serum (NIBRG-107) (Sheep SH503) |
09/110 |
Parvovirus B19 DNA Nucleic Acid Amplification Technology(NAT) based assays Genotype Panel(1st International Standard) |
09/130 |
Influenza Virus Infectious NIBRG-122 |
09/132 |
Human Coronavirus 229E Working Reagent for Nucleic Acid Amplification Testing |
09/136 |
Granulocyte Colony Stimulating Factor (Human, rDNA Derived)(2nd International Standard) |
09/138 |
Genetic Reference Panel, for the quantitation of BCR-ABL translocation by RQ-PCR (1st I.S.) |
09/140 |
Prader Willi & Angelman Syndromes, Human gDNA,(1st International Genetic Reference Panel) |
09/148 |
Influenza anti A/New York/107/2003 (H7) HA serum (Sheep SH504 and SH505) |
09/162 |
Human Cytomegalovirus (HCMV) for Nucleic Acid Amplification Techniques (1st International Standard) |
09/170 |
Anti-Meningococcal factor H binding protein variant 1 (JAR4) monoclonal antibody |
09/172 |
Blood coagulation Factors II, VII, IX, X Plasma (4th International Standard 2010) |
09/174 |
Influenza Antigen A/California/7/09 (H1N1)v (NYMCX-179A)(Cell Derived) |
09/182 |
VWF Factor Concentrate (2nd International Standard) |
09/184 |
Influenza Antigen A/Vietnam/1194/2004 (H5N1) NIBRG-14 |
09/186 |
Chagas (anti-Trypanosoma cruzi II) antibody in human plasma(1st International Standard) |
09/188 |
Chagas (anti-Trypanosoma cruzi I) antibody in Human Plasma (1st International Standard) |
09/196 |
Influenza Antigen A/California/7/09 (H1N1)v (NIBRG-121xp) (Egg Derived) |
09/222 |
Human anti-Haemophilus influenzae b reference serum |
09/234 |
Transforming Growth Factor-BETA 3 (Human, rDNA derived TGF-ß 3) (1st International Standard) |
09/236 |
Influenza Virus Infectious IVR-153 |
09/242 |
Fibrinogen Concentrate (B)(2nd International Standard) |
09/260 |
Epstein-Barr Virus for Nucleic Acid Amplification Techniques(1st International Standard) |
09/264 |
Fibrinogen Plasma (D)(3rd International Standard) |
09/266 |
GLIAL CELL-DERIVED NEUROTROPHIC FACTOR (GDNF), human, rDNA-derived |
09/268 |
Influenza Virus Infectious NIBRG-121xp |
09/272 |
Placental growth factor Ala 21 - Arg 149, human, rDNA-derived (PlGF, PlGF-1) |
09/274 |
Influenza Virus Infectious NYMC X-185 |
09/280 |
Influenza Virus Infectious NIB-64 |
09/284 |
Anti-Human Neutrophil Antibody 1a WHO Reference Reagent |
09/296 |
Pro-Insulin, human (1st International Standard) |
09/304 |
Influenza Virus Infectious IVR-155 |
09/306 |
Influenza Virus Infectious NIBRG-147 (H2N2) |
09/308 |
Influenza Serology Antigen Reagent X-179A (H1N1pdm) for HI Assay |
09/310 |
Influenza Antigen A/Wisconsin/15/09 (H3N2) (NYMCX-183) |
10/104 |
Reteplase Reference Material |
10/120 |
Influenza Anti A/Brisbane/59/2007 (IVR 148)(H1N1) HA serum |
10/128 |
Diphtheria Polyclonal Antibody |
10/130 |
Diphtheria Monoclonal Antibody |
10/132 |
Tetanus Polyclonal Antibody |
10/134 |
Tetanus Monoclonal Antibody |
10/140 |
Anti-human papillomavirus[HPV] 18 serum (1st International Standard) |
10/142 |
Anti-HLA Control |
10/164 |
Oral Poliovaccine Sabin Type 1 reference strain [LS-c, 2ab strain]. |
10/168 |
Oral Poliovaccine Sabin Type 3 reference |
10/176 |
Interleukin-29 (Interferon Lambda, Human, rDNA derived) WHO Reference Reagent |
10/178 |
Endotoxin (3rd International Standard) |
10/198 |
Anti-malaria (Plasmodium falciparum) human serum(1st WHO Reference Reagent) |
10/202 |
Influenza antibody (Human) to A/California/7/2009 'like' (H1N1v) virus (2nd International Standard) |
10/214 |
Influenza Anti N2 Neuraminidase Serum SH395 & SH396 |
10/218 |
Influenza Anti A/California/7/2009 (N1) NA Serum |
10/226 |
Influenza Virus Infectious IVR-158 |
10/232 |
Blood Group Genotyping Reference Reagent RBC1 (OR1R2)(WHO Reference Reagent) |
10/234 |
Blood Group Genotyping Reference Reagent RBC12 (ODpsi)(WHO Reference Reagent) |
10/236 |
Blood Group Genotyping Reference Reagent RBC4 (AR1R1)(WHO Reference Reagent) |
10/238 |
Blood Group Genotyping Reference Reagent RBC5 (Brr)(WHO Reference Reagent) |
10/242 |
Toxoplasma gondii DNA Nucleic Acid Amplification Techniques(1st International Standard) |
10/252 |
Factor VII Concentrate (2nd International Standard) |
10/258 |
Influenza Antigen A/California/7/2009-like(NIB-74) |
10/262 |
Diphtheria Antitoxin Human IgG(1st International Standard) |
10/266 |
4th WHO International Standard for HBV DNA for NAT |
10/272 |
BCG vaccine of Moreau-RJ sub-strain(1st WHO Reference Reagent) |
10/286 |
Follicle Stimulating Hormone, Luteinizing Hormone human, urinary for bioassay(5th International Standard) |
10/B596 |
QCRHSV1QC1-Anti-HSV1 Quality Control Serum: Sample1 |
100976 |
pCAGGS-SARS-CoV-2-Spike |
100978 |
VeroE6/TMPRSS2 |
100980 |
SARS-CoV-2 infectious virus (BetaCoV/Australia/VIC01/2020 |
100982 |
SARS-CoV-2 Nucleoprotein |
100985 |
pCAGGS_SARS-CoV-2_Spike D614G |
100986 |
pCAGGS-SARS-CoV-2-Spike Bristol Deletion |
100987 |
Inactivated SARS-CoV-2 (BetaCoV/Australia/VIC01/2020 |
100988 |
Nucleic acid extracts from inactivated SARS-CoV-2 (BetaCoV/Australia/VIC01/2020 |
100989 |
pCRII-SARS-CoV-2 (5'UTR-NSP2) |
100991 |
pCRII-SARS-CoV-2 (NSP4-NSP8) |
100992 |
pCRII-SARS-CoV-2 (NSP4-NSP8) |
100994 |
pCRII-SARS-CoV-2 (NSP15-NSP16) |
100996 |
pCRII-SARS-CoV-2 (ORF3a-ORF6) |
100998 |
SARS-CoV-2 infectious virus (CVR-GLA 1) |
100999 |
SARS-CoV-2 infectious virus(CVR-GLA 2) |
101000 |
SARS-CoV-2 infectious virus(CVR-GLA 3) |
101001 |
VeroE6-ACE2 |
101003 |
VeroE6-ACE2-TMPRSS2 |
101004 |
A549-ACE2-TMPRSS2 |
101005 |
A549-ACE2 Clone8 |
101006 |
A549-ACE-2 Clone 8-TMPRSS2 |
101007 |
SARS-CoV-2 Trimeric Spike 50ug (1mg/ml in PBS) Sterile #28.05.2020 |
101008 |
HEK293T-ACE2-TMPRSS2 |
101009 |
Anti-SARS-CoV-2 Nucleocaspid protein (CR3009) |
101010 |
Anti-SARS-CoV-2 Nucleocapsid protein (CR3018) |
101011 |
Anti-SARS-CoV-2 Nucleocapsid protein (CR3009 Human/Mouse HC) |
101019 |
VOC-202012/01 (B.1.1.7 lineage) lot 26012021 |
101022 |
SARS-CoV-2 VOC202012/02 (B.1.351 lineage) passage 4 |
101023 |
pl.18SARS-CoV-2-Spike (B.1.1.7) 1ug (100ng/ul) lot #24032021 |
101024 |
pl. 18SARS-CoV-2-Spike (B.1.351) 1ug (100ng/ul) lot #24032021 |
101025 |
4% formaldehyde inactivated SARS CoV-2 BetaCoV/Australia/VIC01/2020 from VeroE6/TMPRSS2 |
101027 |
Acid/heat inactivated SARS-CoV-2 (B.1.1.7) lot 17022021 |
101029 |
SARS-CoV-2 Alpha (B.1.1.7) Purified RNA extracts lot 20052021 |
101030 |
SARS-CoV-2 VOC-202104/02 (B.1.617.2 lineage) |
101031 |
SARS-CoV-2 VOC-21FEB02 (B.1.1.7 lineage + E484K) |
101032 |
SARS-CoV-2 Kappa (B.1.617.1 lineage |
101033 |
SARS-CoV-2 Delta (AY.1 sub-lineage) |
101034 |
SARS-CoV-2 Mu (B.1.621 lineage) |
101035 |
Acid/Heat Inactivated SARS-CoV-2 Beta (B.1.351 lineage) |
101036 |
Acid/Heat Inactivated SARS-CoV-2 Delta (B.1.617.2 lineage |
101038 |
0.01% Formaldehyde Inactivated SARS-CoV-2 Beta (B.1.351 lineage) |
101039 |
0.01% Formaldehyde Inactivated SARS-CoV-2 Delta (B.1.617.2 lineage) |
101042 |
SARS-CoV-2 Nucleocapsid protein (His tagged) |
101043 |
SARS-CoV-2 Nucleocapsid protein 203/204:RG>KR (His tagged) |
101044 |
SARS-CoV-2 Omicron (lineage B.1.1.529) |
1050 |
IPV ELISA MAbs Type 1, 2 and 3 (Type 2; No: 1050) |
11/108 |
Influenza Virus infectious NYMC X-187 |
11/126 |
Factors II and X Concentrate (4th International standard) |
11/134 |
Influenza Antigen A/California/7/2009 (H1N1) Like (A/Brisbane/10/2010- cell derived) |
11/170 |
Erythropoietin, recombinant, for Bioassay (3rd International Standard) |
11/176 |
(3rd International Standard) Low Molecular Weight Heparin |
11/184 |
High Molecular Weight Urokinase(2nd International Standard) |
11/206 |
Influenza anti-A/Perth/16/2009 HA Serum |
11/210 |
Anti-human CD4 FITC conjugated 0.5ml |
11/212 |
Biosynthetic Human Insulin (2nd WHO international Standard) |
11/214 |
Blood Group Genotyping Reference Reagents Panel (WHO Reference Reagent) |
11/216 |
Chagas Antibody Reference Panel ( 1st International Standard) |
11/222 |
Influenza Virus Infectious NIB-79 |
11/232 |
Influenza Virus Infectious B/Texas/6/2011 |
11/234 |
Immunoglobulin E(IgE) human serum (3rd International Standard) |
11/242 |
Viral Multiplex Reference |
11/244 |
Influenza Virus Infectiious NYMC BX-49 |
11/B608 |
QCRHIV1QC1-Anti-HIV1:Quality Control Serum: Sample1 |
12/100 |
Influenza Virus Infectious NYMC X-217 |
12/104 |
International Standard for IPV 12/104 (3rd International Standard) |
12/106 |
Influenza Antigen B/Hubei-Wujiagang/158/2009 (NYMCBX-39) |
12/110 |
Influenza Antigen B/Wisconsin/1/2010 (cell derived) |
12/112 |
Influenza Antigen A/Victoria/210/2009 (H3N2) (NYMCX-187) |
12/114 |
Influenza Antigen A/Victoria/361/2011 (H3N2) (IVR-165) |
12/116 |
Influenza anti-A/Victoria/361/2011-like HA serum |
12/118 |
Influenza anti-B/Wisconsin/1/2010-like HA serum |
12/122 |
Influenza virus infectious A/turkey/Italy/3889/1999 (H7N1) |
12/154 |
Tumour Necrosis Factor alpha (human rDNA derived)(3rd International Standard) |
12/176 |
Methylated Human Serum Albumin (mHSA) |
12/188 |
Pegylated Granulocyte Colony Stimulating Factor (Human, rDNA derived) (1st International Standard) |
12/198 |
Influenza virus infectious B/Wisconsin/1/2010 34490 E5 |
12/202 |
Influenza virus infectious NYMC BX-39 |
12/204 |
Influenza Virus infectious IVR-165 |
12/208 |
Parvovirus B19 (3rd International Standard) |
12/224 |
HIV-1 NAT subtypes (Main)(2nd International Reference Panel Preparation) |
12/226 |
HBsAg (HBV genotype B4, HBsAg subtypes ayw1/adw2)(3rd International Standard) |
12/244 |
Vi polysaccharide of C freundii WHO 1st International Standard |
12/252 |
ADAMTS 13 Plasma (1st International Standard) |
12/278 |
2nd Pneumococcal QC Serum Panel |
12/282 |
Diphtheria Toxin 1Lf/ml |
12/284 |
Anti-meningococcal serogroup Y monoclonal antibody |
12/290 |
Influenza Virus Infectious B/Brisbane/36/2012 |
12/294 |
Influenza Virus Infectious NYMC BX-51C |
12/300 |
Negative Control IVIG (for use with IVIG and Anti-D) |
12/306 |
Haemophilus Influenzae Polysaccharide Polyribosyl Ribitol Phosphate (PRP)(2nd International Standard) |
12/B611 |
Anti-VZV Quality control serum: Sample 1 QCRVZVIgMQC1 |
12/B612 |
QCRRUBIgMQC1-Anti-Rubella IgM Quality Control Serum: Sample 1 |
13/100 |
Activated Blood Coagulation Factor XI (FXIa), Human (1st International Standard) |
13/106 |
Influenza Antigen B/Massachusetts/02/2012 |
13/108 |
Anti-Meningococcal serogroup B monoclonal antibody |
13/112 |
Influenza Antigen A/Texas/50/2012 (NYMC X-223) |
13/116 |
Influenza Antigen A/Texas/50/2012 (NYMC X-223A) |
13/122 |
Erythropoietin Antibody Reference Panel Negative Control Antibody (1st WHO Reference Panel) |
13/126 |
Influenza anti-B/Brisbane/60/2008-like HA serum |
13/128 |
Influenza Virus Infectious NIBRG-269 |
13/132 |
Antibodies, Human, to Toxoplasma gondii (4th International Standard). |
13/134 |
Influenza Antigen B/Massachusetts/02/2012 (Egg derived) |
13/146 |
C-Peptide, Human (1st International Standard). |
13/148 |
IVIG + anti-D for use with negative control IVIG |
13/152 |
Influenza Antigen B/Massachusetts/02/2012 (Cell Derived) |
13/162 |
Influenza Antigen A/Texas/50/2012 (NYMC X-223A) (Cell derived) |
13/164 |
Influenza Antigen A/California/7/2009 (H1N1pdm)(NYMC X-179A) |
13/166 |
Influenza anti-A/Anhui/1/2013 (N9) NA Serum |
13/168 |
Human Measles Mvi/Moscow Rus/1988 Genotype A Virus for Nucleic Acid Amplification Techniques |
13/172 |
Lupus Anticoagulant (1st International Reference Panel) |
13/176 |
Influenza Virus Infectious NIBRG-88 |
13/178 |
Influenza Anti-A/Texas/50/2012-like HA Serum |
13/182 |
Influenza Anti-B/Massachusetts/02/2012-like HA Serum |
13/200 |
Influenza Virus Infectious NIB-74 |
13/202 |
Influenza Virus Infectious NIB-74xp |
13/204 |
TNF Rec II- FC Fusion protein (1st International Standard) |
13/206 |
Plasmin (4th International Standard) |
13/212 |
Diphtheria Toxoid for use in Flocculation Test (3rd International Standard) |
13/214 |
HIV-1 Circulating Recombinant Forms RNA (1st International Reference Panel) |
13/216 |
Anti-meningococcal factor H binding protein variant 1 (JAR5) monoclonal |
13/218 |
Polio Anti Sabin type 1 (inactivated) Serum |
13/220 |
Polio Anti Sabin type 2 (inactivated) serum |
13/222 |
Polio Anti Sabin type 3 (inactivated) serum |
13/224 |
Influenza virus Infectious NIB-85. 36210 E5 |
13/228 |
Influenza Virus Infectious. A/Almaty/2958/2013. 35790 E4 |
13/234 |
Influenza antigen B/Brisbane/60/08 |
13/238 |
Anti-EV71 serum LOW (WHO Reference Reagent) |
13/240 |
Tetanus Immunoglobulin, Human (2nd WHO International Standard) |
13/242 |
FEIBA Concentrate 2nd NIBSC Working Reference Standard |
13/246 |
Meningococcal serogroup A polysaccharide (1st WHO International Standard). |
13/248 |
Influenza virus infectious NIBRG-267 (H7N9) |
13/250 |
Influenza Virus Infectious NIBRG-268 (H7N9) |
13/252 |
Influenza virus infectious NYMC X-223A |
13/256 |
Influenza virus infectious. NYMC x-233 |
13/258 |
Influenza virus infectious NYMC X-233A |
13/262 |
Meningococcal serogroup A polysaccharide |
13/264 |
Influenza Virus Infectious NYMC X-223 |
13/B627 |
QCRMALQC1-Anti-Malaria Quality Control Serum: Sample1 |
13/B629 |
QCRHBeQC1 Anti-HBe Control Serum: sample1 |
13/B634 |
QCRHAVIgMQC2 IgM Anti-HAV Quality Control Serum: Sample2 |
13/B640 |
QCRHIV1QC5 - Anti-HIV-1 Quality Control Reagent Sample 5 |
13/B642 |
QCRHSV2QC1-Anti-HSV2 Quality Control Serum: Sample 1 |
13/B644 |
QCRHIV1QC3-Anti-HIV1:Quality Control Serum:Sample 3 |
14/100 |
Human Papillomavirus (HPV) 11 DNA (1st International Standard) |
14/104 |
Human Papillomavirus (HPV) Type 45 DNA (1st International Standard) |
14/106 |
Influenza virus infectious. NYMC BX-51B |
14/114 |
JC Virus (JCV) DNA (1st International Standard) |
14/116 |
Influenza virus infectious NYMC X-179A |
14/118 |
Influenza virus infectious B/Massachusetts/2/2012 |
14/140 |
1st International Standard for Anti EV71 Serum Human |
14/144 |
Influenza anti-N2 Neuraminidase serum (A/Victoria/361/2011) |
14/146 |
Influenza Antigen B/Brisbane/60/2008 (NYMCBX-35)(Cell Derived) |
14/148 |
Human Blood Factor IX Concentrate (5th International Standard). |
14/156 |
Meningococcal group X polysaccharide (1st WHO International Standard) |
14/160 |
High titre anti-A in IVIG working reference reagent |
14/174 |
Botulinum Type A Antitoxin, Equine |
14/198 |
HBV,HCV,HIV Multiplex |
14/200 |
Influenza Antigen A/Puerto Rico/8/34 (HINI) |
14/206 |
Influenza virus infectious NYMC X-247 |
14/210 |
Biological activities of Rituximab WHO 1st International Standard |
14/212 |
BK Virus (BKV)(1st International Standard) |
14/224 |
Influenza virus infectious. A/Switzerland/9715293/2013 |
14/226 |
Influenza Virus Infectious A/South Australia/55/2014 |
14/228 |
Influenza Virus Infectious A/Stockholm/6/2014 |
14/230 |
Influenza Virus Infectious. A/Norway/466/2014 |
14/232 |
Influenza Virus Infectious IVR-175 |
14/238 |
Recombinant Tissue factor |
14/254 |
Influenza Antigen A/Switzerland/9715293/2013 (NIB88) |
14/256 |
Human Papillomavirus (HPV) Type 6 DNA (1st International Standard) |
14/258 |
Human Papillomavirus (HPV) Type 31 DNA (1st International Standard) |
14/260 |
Human Papillomavirus (HPV) Type 33 DNA (1st International Standard) |
14/262 |
Human Papillomavirus (HPV) Type 52 DNA (1st International Standard) |
14/264 |
Human Papillomavirus (HPV) Type 58 DNA (1st International Standard) |
14/274 |
Influenza Antigen B/Brisbane/9/2014 (Egg Derived) |
14/300 |
High titre anti-A and anti-B in serum (WHO Reference Reagent). |
14/306 |
Influenza Virus Infectious NYMC X-243 40180 E13 |
14/308 |
Influenza Virus Infectious IVR-178 40200 E7 |
14/314 |
Influenza Virus Infectious NIB-88 |
14/316 |
Factor IX activated (FIXa) 2nd WHO International Standard |
14/318 |
Influenza Anti NIBRG-301 (H5) HA Serum (Sheep SH624 and SH625) |
14/322 |
Influenza Virus Infectious NIB-91 |
14/B651 |
QCRTHBcQC2-Total Anti-HBc Quality Control Serum: Sample2 |
14/B653 |
QCRHIV2QC3- Anti HIV2: Quality Control Serum: Sample 3 |
14/B654 |
QCRRUBQC1-Anti-Rubella Quality Control Serum: Sample 1 |
14/B655 |
QCRVZVQC1-Anti VZV: Quality Control Serum: Sample 1 |
15/100 |
Influenza Antigen B/Utah/9/2014 (Cell Derived) |
15/102 |
Activated Blood Coagulation Factor X (FXa), Human |
15/104 |
Influenza Antigen A/South Australia/55/2014 Cell derived |
15/106 |
Ancrod |
15/126 |
Bordetella pertussis toxin (20µg). (2nd International Standard) |
15/130 |
Clinical Virology Multiplex I: Immunodeficiency panel working reagent for Nucleic Acid Amplification Tests (NAT) |
15/134 |
Influenza Anti-A Switzerland/9715293/2013-Like HA serum |
15/136 |
EBOV RNA NP-VP35-GP in-run control |
15/138 |
EBOV RNA VP40-L in-run control |
15/140 |
Batroxobin |
15/148 |
Influenza Virus Infectious NIB-92 |
15/154 |
Influenza Virus Infectious NIB-93 |
15/158 |
Influenza Virus Infectious NYMC X-263 |
15/160 |
Influenza Virus Infectious NIBRG-306 |
15/174 |
Lupus (oligo-specific) anti-dsDNA antibodies WHO Reference Reagent |
15/180 |
Blood Coagulation Factor XI, 2016 Plasma Human (2nd International Standard). Blood Coagulation Factor XII, 2017 Plasma, Human (1st International Standard) |
15/182 |
7th British Working Standard for Blood Coagulation Factors II, IX, X Concentrate |
15/184 |
Influenza Virus Infectious NYMC X-263B |
15/188 |
Influenza Virus Infectious NYMC X-263A |
15/194 |
Influenza Virus Infectious NYMC X-257A |
15/196 |
Influenza Virus Infectious NYMC X-261 |
15/212 |
Influenza Virus Infectious NYMC BX-53C |
15/220 |
Anti-EBOV plasma, human (WHO Reference Reagent) |
15/222 |
EBOV RNA NP-VP35-GP (WHO Reference Reagent) |
15/224 |
EBOV RNA VP40-L (WHO Reference Reagent) |
15/234 |
Influenza Virus Infectious B/Texas/2/2013 41340 E7 |
15/238 |
Influenza Antigen A/New Caledonia/71/2014 (NYMCX-257A)(Egg derived antigen) |
15/240 |
Erythropoietin Antibody Reference Panel A (1st WHO Reference Panel) |
15/242 |
Erythropoietin Antibody Reference Panel B (1st WHO Reference Panel) |
15/248 |
Influenza Anti A/Anhui/1/2013 (H7) HA Serum (Sheep SH644 & SH645) |
15/250 |
Influenza Virus Infectious NYMC BX-31 |
15/252 |
Influenza Virus Infectious A/California/7/2009 |
15/262 |
1st International Standard for Ebola virus (EBOV) antibodies Sierra Leone Convalescent Plasma Pool |
15/266 |
HHV-6 Virus 1st WHO International Standard |
15/270 |
CD4 WHO Reference Reagent |
15/272 |
ICS Positive Control-Lymphocytes |
15/276 |
Hepatitis A Virus VL For Nucleic Acid Amplification Techniques (3rd International Standard) |
15/294 |
Influenza virus infectious NYMC BX-59B |
15/296 |
Sabin monovalent Polio vaccine type 2 (1st International Standard) |
15/298 |
Influenza Virus Infectious B/Brisbane/46/2015 |
15/300 |
Influenza Virus Infectious NYMC BX-35 41950 E11 |
15/304 |
Parathyroid hormone 1-34, recombinant, human, 2nd WHO International Standard |
15/B658 |
QCRLYMEQC1 - Anti-Lyme QC1 |
15/B664 |
QCRMUMPSQC1 - Anti-Mumps Quality Control Reagent Sample 1 |
15/B667 |
QCRMEASQC1 Anti-Measles QC1 |
15/B671 |
QCRHIV1P24QC1-HIV1 p24 Antigen: Quality Control Serum: Sample1 |
15/B678 |
QCRPARVB19QC1 Anti-Parvovirus B19QC1 |
15/B680 |
QCRHBsQC1- Anti HBs Quality Control Serum: Sample 1 |
16/104 |
Norovirus GII Working reagent for Nucleic Acid Amplification Techniques |
16/106 |
Influenza antigen A/California/7/09 (H1N1) (NYMC-X181) |
16/108 |
Influenza Virus Infectious A/PR/8/34 |
16/110 |
Zika Virus Working Reagent for Nucleic Acid Amplification Testing (NAT) |
16/114 |
Influenza anti - A/California/7/09 HA serum |
16/118 |
Influenza Antigen B/Brisbane/60/2008 (NYMC BX-35) (Egg Derived) |
16/120 |
WHO 1st International Reference Panel for Genomic JAK2 V617F |
16/126 |
Native Vi polysaccharide (S. Typhi) (1st International Standard) |
16/138 |
Anti-Typhoid capsular Vi polysaccharide Ig (Human) 1st WHO International Standard |
16/152 |
Meningococcal Serogroup W Polysaccharide |
16/164 |
Sabin bivalnet Polio vaccines types 1 and 3 (1st International Standard) |
16/170 |
Infliximab (1st International Standard) |
16/182 |
Influenza Anti-A/Hong Kong/4801/2014-like HA Serum |
16/190 |
Mullerian Inhibiting Substance/Anti-Mullerian Hormone, human, recombinant (WHO reference Reagent) |
16/192 |
Influenza Anti - B/Brisbane/60/2008-HA serum |
16/194 |
HIV-1 RNA (4th International Standard) |
16/196 |
Sabin monovalent Polio vaccine type 1(1st International Standard) |
16/200 |
Influenza Virus Infectious NIB-58 |
16/202 |
OPV reference mOPV 3 |
16/204 |
7th WHO International Standard for Rabies Vaccine |
16/206 |
Meningococcal serogroup Y Polysaccharide |
16/208 |
Influenza Virus Infectious NIB-97 42090 E7 |
16/210 |
HIV-1 P24 Antigen (1st international reference panel) |
16/236 |
HIV-2 p26 Antigen (VLP)-HIV-2 A7312 (1st WHO Reference Reagent) |
16/238 |
Influenza Antigen A/Anhui/1/2013 (NIBRG-268) (H7N9) |
16/242 |
Influenza Virus Infectious NIB-98 42110 E7 |
16/250 |
1st International Reference Panel for genomic KRAS codons 12 and 13 mutations |
16/268 |
Influenza Virus Infectious X-273 |
16/270 |
Influenza Virus Infectious IVR-180 42400 E3/D7/E1 |
16/274 |
Influenza Virus Infectious X-275A 42010 E13 |
16/278 |
Anti-D Immunglobulin control preparation |
16/282 |
Influenza Virus Infectious X-285 42430 ExE1 |
16/284 |
Antiserum to Respiratory Syncytial Virus WHO 1st International Standard |
16/286 |
Influenza Antigen A/Hong Kong/4801/2014 (NYMC X-263B) |
16/288 |
Influenza Virus Infectious X-283A 42420 ExE1 |
16/290 |
Influenza Virus Infectious X-285A 42440 ExE1 |
16/292 |
Influenza Antigen A/Singapore/GP1908/2015 (IVR-180) |
16/296 |
Human Immunodeficiency Virus type 2 RNA (HIV-2) for Nucleic Acid Amplification Techniques (2nd International Standard) |
16/302 |
Tetanus Toxoid for use in Flocculation Test (3rd International Standard) |
16/320 |
Zika Antibody Working reagent |
16/324 |
Human Adenovirus DNA for nucleic acid amplification techniques (1st WHO international Standard). |
16/332 |
Anti-D Immunoglobulin (Replacement IS) |
16/344 |
WHO Anti-EBOV Convalescent Plasma (International Reference Panel) |
16/352 |
Anti-Asian Lineage Zika Virus Antibody (human) (1st international standard) |
16/358 |
Streptokinase (4th WHO International Standard) |
16/360 |
Influenza Virus Infectious NIB-96 41920 E7 |
16/362 |
Influenza Virus Infectious NYMC X-291 42530 E8 |
16/364 |
3rd International Standard for Prekallikrein Activator |
16/366 |
Influenza Virus Infectious NYMC X-291A 42540 E8 |
16/368 |
HSV-1 |
16/374 |
Blood Coagulation Factor V, Plasma, Human. (WHO 2nd International Standard) |
16/376 |
Plasmodium falciparum antigens (1st International Standard) |
16/B687 |
QCRHIV1RTDQC1- Anti-HIV1 Quality Control Serum: Sample 1 for Rapid Test Devices |
16/B693 |
QCRCMVIgMQC1 IgM Anti-CMV QC1 |
16/B695 |
QCRTOXOIgMQC1 IgM Anti-Toxoplasma gondii QC1 |
16/B697 |
QCREBVVCAQC1 |
16/B704 |
QCRTHBcQC1-Total Anti-HBc Quality Control Serum: Sample 1 |
16/B707 |
QCREBVNEGQC1 |
17/100 |
Prostate Specific Antigen (human)(total: PSA-ACT + free PSA) |
17/102 |
Prostate Specific Antigen (human) (Free), (2nd WHO International Standard) |
17/106 |
Influenza Anti-A/Michigan/45/2015-like HA Serum |
17/122 |
HSV-2 |
17/124 |
Influenza Virus Infectious NYMC BX-63 42790 E10/E1 |
17/126 |
Influenza Virus Infectious NYMC BX-63A 42780 E10/E1 |
17/132 |
Influenza Anti NIBRG-306 (H5) HA Serum (sheep SH672 and SH637) |
17/136 |
Influenza Virus Infectious NIBRG-375 (H7N9) |
17/142 |
Influenza Antigen A/Duck Vietnam/NCVD-1584/2012 (NIBRG-301) (H5N1) |
17/154 |
Influenza Antigen A/Michigan/45/2015 (NYMC X-275) |
17/156 |
Influenza Virus Infectious CNIC-1701 42910 E9 |
17/160 |
Sabin Inactivated Polio Vaccine (sIPV) (WHO 1st international Standard) |
17/162 |
Influenza Virus Infectious NYMC X-299 42920 E10 |
17/164 |
Influenza Virus Infectious B/Maryland/15/2016 42800 E5 |
17/182 |
Influenza Antigen A/Michigan/45/2015 (NYMC X-275) |
17/184 |
Influenza Virus Infectious NIB-103 42610 E7 |
17/190 |
Influenza Virus Infectious NYMC X-297 42940 E11 |
17/194 |
Influenza Virus Infectious NIB-104 |
17/204 |
1st International Standard for Darbepoetin |
17/206 |
14th British Standard for Coagulation Factor VIII Concentrate, Human. |
17/210 |
Influenza Virus Infectious IVR-186 43310 E8 |
17/212 |
Anti-HLA Negative Control for FCXM and bead- based assays |
17/232 |
Tumor Necrosis Factor alpha (human rDNA derived) |
17/236 |
Adalimumab (1st WHO International Standard) |
17/238 |
Anti-HLA Positive Control for FCXM and bead-based assays |
17/240 |
5% Immunoglobulin (Negative Control) |
17/246 |
Influenza Antigen A/Singapore/INFIMH-16-0019/2016 (NIB-104) |
17/252 |
Influenza Virus Infectious NYMC BX-69 43220 E13 |
17/256 |
Influenza Virus Infectious NYMC BX-69A |
17/258 |
Influenza Virus Infectious B/Alabama/2/2017 |
17/264 |
Influenza Virus Infectious A/Michigan/45/2015 43470 E5 |
17/B710 |
QCRTOXOQC1 - Anti-Toxoplasma gondii Quality Control Reagent Sample 1 |
17/B713 |
QCRSYPHQC2-Anti-Syphilis Quality Control Serum: sample 2 |
17/B717 |
QCRHBsGQC1-HBsAg Quality Control Serum: Sample1 |
17/B718 |
QCRHBsGQC2-HBsAg Quality Control Serum: Sample2 |
17/B723 |
QCRHEVQC1 - Anti-Hepatitis E Quality Control Sample 1 |
17/B725 |
QCRTHAVQC1-Total Anti-HAV Quality Control Serum: Sample1 |
17/B728 |
QCRHEVIgMQC1 - IgM Anti-Hepatitis E Quality Control Sample 1 |
18/100 |
Influenza Antigen B/Maryland/15/2016 |
18/104 |
Influenza Antigen B/Maryland/15/2016 (NYMC BX-69A) |
18/108 |
Influenza anti-A/Singapore/INFIMH-16-0019/2016- like HA serum |
18/110 |
Influenza Antigen A/Singapore/INFIMH-16-0019/2016 (IVR-186) |
18/112 |
Influenza anti-A/Guangdong-17SF003/2016 (H7) (NIBRG-375) HA Serum |
18/116 |
WHO International Standard Enterovirus 71 (EV71) Inactivated vaccine (Geno Group C4) |
18/118 |
1st International Standard for HCT 15 Cancer Genome |
18/120 |
WHO Reference Reagent Enterovirus 71 (EV71) Inactivated Vaccine (Geno Group C4) |
18/130 |
1st International Standard for MOLT-4 Cancer Genome |
18/134 |
Influenza Virus Infectious NIBRG-301 (H5N1) |
18/136 |
Influenza Virus Infectious NIBRG-14 (H5N1) |
18/138 |
Influenza Virus Infectious NYMC X-307A |
18/140 |
Influenza Virus Infectious NYMC X-307 |
18/144 |
WHO 1st Reference Reagent for Lentiviral Vector Integration Site Analysis |
18/146 |
Pertussis antiserum (human) panel |
18/154 |
Bordetella pertussis, pertactin, PRN |
18/156 |
WHO Reference Reagent Enterovirus 71 (EV71) Inactivated Vaccine (Geno Group B4) |
18/160 |
Influenza Virus Infectious NYMC X-311 |
18/164 |
1st International Standard for ATDB102 Genome |
18/166 |
Influenza Virus Infectious NIB-112 43990 E6 |
18/168 |
Influenza Virus Infectious A/Switzerland/8060/2017 |
18/170 |
Influenza anti-B/Colorado/06/2017-like HA serum |
18/174 |
Influenza Virus Infectious A/Brisbane/1/2018 |
18/184 |
Hepatitis C virus RNA for nucleic acid amplification techniques (6th WHO International Standard) |
18/188 |
Influenza Antigen A / Switzerland / 8060 / 2017 (NIB-112) |
18/190 |
Influenza Antigen A / Brisbane/ 01/2018 (NYMC X-311) |
18/192 |
Influenza Anti-A/Switzerland/8060/2017-like (H3N2) HA Serum |
18/194 |
Influenza Virus Infectious NYMC X-275 (Influenza Reagent) |
18/196 |
Influenza Antigen A/Guangdong/17SF003/2016. NIBRG-375 (H7N9) |
18/206 |
West Nile Virus - International Standard |
18/208 |
WHO Reference Reagent for West Nile Virus lineage 2 RNA for NAT-based assays |
18/210 |
Bevacizumab (1st WHO International Standard) |
18/220 |
Anti-HPA 15b minimum potency reagent (WHO Reference Reagent) |
18/226 |
Influenza Virus Infectious IVR-190 44250 E12 |
18/230 |
Influenza Virus Infectious B/Colorado/06/2017 43460 E7 |
18/234 |
Influenza Virus Infectious NIB116-B 44230 E5 |
18/236 |
Influenza Virus Infectious A/Brisbane/02/2018 |
18/238 |
Influenza Antigen A/Brisbane/02/2018 (IVR-190) (H1N1) |
18/240 |
Influenza Virus Infectious NYMC X-327 44280 E17 |
18/242 |
Influenza Virus Infectious A/Kansas/14/2017 43880 E8 |
18/244 |
Human Chorionic Gonadotropin (hCG) (6th International Standard) |
18/B731 |
Anti CMV QC1 QCRCMVQC1 |
18/B732 |
QCRNEGQC1-Negative Quality Control Serum: Sample1 |
18/B733 |
QCREBVIgMQC1 |
18/B742 |
QCRLYMEIgMQC1 IgM Anti-Lyme QC1 |
19/102 |
Influenza anti-A/Brisbane/02/2018-like (H1N1) HA Serum (Sheep 698, 699, 700, 701) |
19/104 |
Influenza antigen A/Kansas/14/2017 (NYMC X-327) (H3N2) |
19/106 |
Influenza Virus Infectious IVR-195 44300 E9 |
19/108 |
Trastuzumab (1st WHO international Standard) |
19/112 |
Influenza Virus Infectious NIB-110 |
19/116 |
1st WHO Plasmodium Vivax Antigen (LDH) |
19/118 |
Ferritin (Human, Recombinant) |
19/120 |
Influenza Virus Infectious X-327 A 44310 E18 |
19/146 |
Influenza Virus Infectious CNIC-1903 |
19/148 |
Influenza Virus Infectious CNIC-1902 44320 E10 |
19/152 |
Influenza anti-A/Kansas/14/2017 - Like (H3N2) HA Serum |
19/154 |
Influenza Antigen A/Kansas/ 12/2017 (IVR-195) (H3N2) |
19/156 |
Panel of recombinant antibody controls for Cytokine Release Assays |
19/160 |
Influenza Virus Infectious A/California/7/09 44430 E6 |
19/164 |
VZV Nucleic acid amplification techniques (1st WHO International Standard) |
19/166 |
Insulin-like Growth Factor I, for Immunoassay (2nd WHO international Standard) |
19/172 |
Influenza Virus Infectious BVR-11 |
19/174 |
Influenza Virus Infectious IVR-197 (H3N2) 44850 E14 |
19/176 |
Influenza Virus Infectious B/Victoria/705/2018 |
19/178 |
1st WHO International Standard for Anti-MERS-CoV Immunoglobulin G (Human) |
19/180 |
Non WHO Reference material Working reagent for Anti-MERS-CoV Antibody |
19/188 |
3rd International Standard Thrombin |
19/192 |
Influenza Virus Infectious IVR-202 (H3N2) 44880 E10 |
19/194 |
Influenza Virus Infectious B/Brisbane/35/2018 |
19/198 |
1st WHO Reference Reagent for anti-malaria (Plasmodium Vivax) human plasma |
19/204 |
Influenza Antigen A/Newcastle/82/2018 (H3N2) (cell derived) |
19/206 |
Influenza Virus Infectious X-181 45030 E8 |
19/208 |
Influenza Antigen B/Victoria/705/2018 (BVR-11) (B Victoria Lineage) |
19/210 |
Influenza Antigen B/Darwin/7/2019 (B Victoria Lineage) (Cell Derived) |
19/212 |
Influenza Antigen A/South Australia/34/2019 (IVR-197) (H3N2) |
19/216 |
Influenza Anti-A/South Australia/34/2019-Like (H3N2) HA Serum (Sheep 712, 713, 714, 715, 716) |
19/224 |
Collection of WHO International Standards for Human Papillomavirus (HPV) DNA genotypes HPV16, HPV18, HPV6, HPV11 |
19/226 |
Collection of WHO International Standards for Human Papillomavirus (HPV) DNA genotypes HPV31, HPV33, HPV45, HPV52, HPV58 |
19/228 |
Influenza Virus Infectious A/South Australia/34/2019 |
19/230 |
Influenza Virus Infectious A/Christchurch/516/2019 H3N2 45010 E4 |
19/236 |
Diphtheria Antitoxin Equine (DI) (WHO International Standard) |
19/238 |
Influenza Antigen B/Washington/02/2019 9B Victoria Lineage) |
19/240 |
British Working Standard for Anti-HCV |
19/242 |
British Working Standard for Anti HCV 1 in 8 Dilution |
19/256 |
Influenza Virus Infectious BX-85C 45230 E13 |
19/258 |
Influenza Virus Infectious CNIC-1906 44910 E3+3/E9/E1 |
19/260 |
Anti-thyroid peroxidase antibodies (1st WHO International Standard) |
19/276 |
Influenza Virus Infectious NIB-121 (H3N2) 45180 E7/E1/E5 |
19/304 |
Research reagent for SARS-CoV-2 RNA |
19/306 |
Influenza Antigen A/Victoria/2454/2019 (IVR-207) (H1N1) |
19/308 |
Influenza Antigen B/Singapore/INFTT-16-0610/2016 (B Yamagata lineage) (cell derived) |
19/312 |
Influenza Antigen A/Guangdong-Maonan/SWL1536/2019 (CNIC-1909) (H1N1) |
19/314 |
Influenza Anti-A/ Guangdong-Maonan/SWL 1536/2019-like (H1N1) HA Serum (Sheep 723, 724, 725, 726, 727, 728) |
19/316 |
Influenza anti-A/hongKong/2671/2019-like (H3N2) HA Serum (Sheep 729, 730, 731, 732, 733, 734) |
19/318 |
Influenza anti-B/Washington/02/2019-like (B Victoria lineage) HA Serum (Sheep 737, 738, 739, 740, 741, 742) |
19/320 |
Influenza anti-N2 Neuraminidase Serum (A/South Australia/34/2019) (Sheep 735, 736) |
19/322 |
Influenza anti-B/Phuket/3073/2013-like (B Yamagata Lineage) HA serum (Sheep 743, 744, 745, 746, 747, 748) |
19/B747 |
QCRHIV2QC4 - Anti HIV2 Quality Control Serum Sample 4 |
19/B754 |
Anti-Rubella QC2 |
20/102 |
Influenza Virus Infectious IVR-207 (H1N1) 45370 E4/E6/E1 |
20/104 |
Influenza Virus Infectious IVR-208 (H3N2) 45330 E7/E10/E1 |
20/106 |
Influenza Virus Infectious A/Victoria/2454/2019 (H1N1) 45360 E4/E1 |
20/108 |
Influenza Antigen A/HongKong/2671/2019 (NIB-121)(H3N2) |
20/110 |
SARS-CoV-2 (NAT) |
20/112 |
IVIG + Anti-D (13/148)x2 Negative Control IVIG (12/300) x2 |
20/132 |
Influenza Antigen A/HongKong/2671/2019 (IVR-208) (H3N2) |
20/134 |
Influenza Virus Infectious BX-57 45430 E4/E10/E1 |
20/138 |
Working Reagent for SARS-CoV-2 RNA |
20/146 |
First WHO International Standard for SARS-CoV-2 RNA |
20/152 |
First WHO International Standard for Mycobacterium tuberculosis (H37Rv) DNA for NAT-based assays |
20/162 |
NIBSC Anti-SARS-CoV-2 Antibody Diagnostic Calibrant |
20/164 |
Influenza Virus Infectious BX-87C (B/VIC) 45460 E3/E10/E1 |
20/170 |
NHS winter Multiplex Working Reagent for Nucleic acid amplification testing (NAT) |
20/180 |
Influenza A (H1N1) Panel |
20/182 |
Influenza A (H3N2) Panel |
20/184 |
Influenza B Panel |
20/186 |
RSV A Panel |
20/188 |
RSV B Panel |
20/190 |
SARS-CoV-2 Panel |
20/202 |
Anti-Lassa Virus Antibodies (1st International Standard) |
20/214 |
Influenza Virus Infectious IVR-216 (H1N1) 45630 E4/D6/E1 |
20/218 |
Follicle Stimulating Hormone (3rd International Standard) |
20/220 |
Influenza Virus Infectious IVR-217 (H1N1) 45640 E4/D6/E1 |
20/232 |
Influenza Antigen A/Victoria/2570/2019 (IVR-215) (H1N1) |
20/234 |
Influenza Anti-A/Victoria/2570/2019-like (H1N1) HA Serum (Sheep 749, 750, 751, 752, 753, 754) |
20/236 |
Influenza Virus Infectious X-349 (H1N1) E3/E9/E1 45720 |
20/238 |
Influenza Virus Infectious X-349A (H1N1) E3/E11/E1 45730 |
20/264 |
Influenza Virus Infectious X-341 + 1P (H3N2) |
20/266 |
Nucleic Acid Amplification Technique (NAT) Panel for SARS-CoV-2 |
20/294 |
Influenza Virus Infectious X-347 (H3N2) |
20/296 |
Influenza Virus Infectious X-347A (H3N2) |
20/310 |
Influenza Virus Infectious A/Cambodia/E0826360/2020 (H3N2) |
20/318 |
Influenza Virus Infectious IVR-221 (H3N2) |
20/322 |
Influenza Virus Infectious A/Singapore/INFIMH-16-0019/2016 (H3N2) |
20/B758 |
QCRHIV1p24QC2-HIV1 p24 Antigen: Quality Control Serum: Sample2 |
20/B762 |
Anti-HIV Quality Control Serum sample 2 |
20/B764 |
QCRSARSCoV2QC1 |
20/B767 |
QCRSYPHQC1-Anti-Syphilis Quality Control Serum: Sample 1 |
20/B770 |
Anti-SARS-CoV-2 Verification Panel for Serology Assays |
20/B774 |
QCRPARVB19IgMQC1 - IgM Anti-Parvovirus B19 Quality Control Reagent 1 |
21/100 |
Influenza Antigen A/Cambodia/e0826360/2020 (IVR-224) (H3N2) |
21/116 |
Influenza Antigen A/Tasmania/503/2020 (IVR-221) (H3N2) |
21/118 |
Influenza anti-A/Cambodia/e0826360/ 2020-Like (H3N2) HA Serum |
21/122 |
Influenza Virus Infectious X-357A (H3N2) |
21/124 |
Influenza Virus Infectious B/HongKong/574/2019 (B-Victoria lineage) |
21/126 |
NIBSC Reference Reagent for gut microbiome analysis by NGS (DNA-Gut-Mix) |
21/128 |
NIBSC Reference Reagent for Gut microbiome analysis by NGS (DNA-GUT-HiLo) |
21/130 |
Influenza Virus Infectious SAN-004A (H3N2) |
21/132 |
Influenza Virus Infectious B/Phuket/3073/2013 (B-Yamagata lineage) |
21/136 |
Influenza Antigen B/Phuket/3073/2013 (B Yamagata lineage) |
21/148 |
Influenza Virus Infectious X-359 (H3N2) |
21/150 |
Influenza Virus Infectious X-359A (H3N2) |
21/156 |
Influenza Virus Infectious BX-93A (B-Victoria Lineage) |
21/158 |
Influenza Virus Infectious BX-93B (B-Victoria Lineage) |
21/160 |
Influenza Virus Infectious X-353 (H3N2) |
21/164 |
Influenza Virus Infectious X-355B (H3N2) |
21/166 |
Influenza Virus Infectious X-355A-CL (H3N2) |
21/180 |
Meningococcal Capsular Group W polysaccharide |
21/186 |
Influenza Virus Infectious A/Tasmania/503/2020 (H3N2) |
21/190 |
Influenza Virus Infectious X-361A (H3N2) |
21/192 |
Influenza Virus Infectious BX-97A (B-Victoria Lineage) |
21/194 |
Influenza Virus Infectious A/Hong Kong/2671/2019 |
21/196 |
Influenza Virus Infectious IVR-224 (H3N2) |
21/204 |
Influenza Virus Infectious IVR-227 (H3N2) |
21/212 |
Influenza Virus Infectious A/Darwin/6/2021 (H3N2) |
21/214 |
Influenza Virus Infectious A/Darwin/9/2021 (H3N2) |
21/216 |
Influenza Virus Infectious BVR-25 (B-Victoria Lineage) |
21/218 |
Influenza Virus Infectious BVR-26 (B/Victoria Lineage) |
21/224 |
Influenza Virus Infectious B/Austria/1359417/2021 (B/Victoria Lineage) |
21/226 |
Influenza Virus Infectious NIB-127 (H3N2) |
21/228 |
Influenza Virus Infectious NIB-126 (H3N2) |
21/234 |
Working reagent for anti-SARS-CoV-2 immunoglobulin |
21/238 |
Influenza Virus Infectious A/Guangdong-Maonan/SWL/1536/2019 (H1N1) |
21/240 |
Influenza Virus Infectious CNIC-1909 (H1N1) |
21/242 |
Influenza Virus Infectious B/Singapore/WUH4618/2021 (B-Victoria Lineage) |
21/244 |
Influenza Virus Infectious B/Michigan/1/2021 (B/Victoria Lineage) |
21/246 |
Influenza Virus Infectious IVR-228 (H3N2) |
21/248 |
Influenza Virus Infectious BVR-27 (B-Victoria Lineage) 46580 |
21/252 |
Influenza Virus Infectious IVR-215 (H1N1) |
21/268 |
Anti-pneumococcal serotype 1 monoclonal antibody |
21/270 |
Anti-pneumococcal serotype 3 monoclonal antibody |
21/272 |
Anti-pneumococcal serotype 5 monoclonal antibody |
21/274 |
Anti-pneumococcal serotype 6A / 6C monoclonal antibody |
21/276 |
Anti-pneumococcal serotype 7F monoclonal antibody |
21/278 |
Anti-pneumococcal serotype 8 monoclonal antibody |
21/280 |
Anti-pneumococcal serotype 9N monoclonal antibody |
21/282 |
Anti-pneumococcal serotype 9V monoclonal antibody |
21/284 |
Anti-pneumococcal serotype 10A monoclonal antibody |
21/286 |
Anti-pneumococcal serotype 12F monoclonal antibody |
21/288 |
Anti-pneumococcal serotype 14 monoclonal antibody |
21/290 |
Anti-pneumococcal serotype 18C monoclonal antibody |
21/292 |
Anti-pneumococcal serotype 19A monoclonal antibody |
21/294 |
Anti-pneumococcal serotype 22F monoclonal antibody |
21/298 |
Influenza Virus Infectious A/Michigan/173/2020 (H3N2) |
21/306 |
Influenza Virus Infectious SAN-010 (H3N2) |
21/314 |
Influenza Antigen A/Darwin/6/2021 (IVR-227) (H3N2) |
21/316 |
Influenza Antigen B/Austria/1359417/2021 (BVR-26) (B Victoria Lineage) |
21/318 |
Influenza Antigen A/Darwin/9/2021 (IVR-228) (H3N2) |
21/320 |
Influenza Antigen A/Darwin/9/2021 (SAN-010) (H3N2) |
21/322 |
Influenza Anti-B Neuraminidase Serum (B/Phuket/3073/2013) |
21/324 |
Influenza Anti-A/Darwin/9/2021-Like (H3N2) HA Serum |
21/326 |
Influenza Anti-B/Austria/1359417/2021 Like (B Victoria Lineage) HA Serum |
21/330 |
Influenza Antigen B/Michigan/01/2021 |
21/332 |
1st International Reference Panel for anti-Lassa fever virus antibodies |
21/336 |
Influenza Virus Infectious B/Washington/02/2019 (B-Victoria lineage) |
21/346 |
Influenza Virus Infectious A/Victoria/2570/2019 (H1N1) |
21/348 |
Influenza Virus Infectious B/Utah/9/2014 (B-Yamagata lineage) |
21/350 |
Influenza Virus Infectious BX-59A (B-Yamagata lineage) |
21/352 |
Influenza Virus Infectious B/Brisbane/9/2014 (B-Yamagata) |
21/366 |
Influenza Virus Infectious SAN-011 (H1N1) |
21/B777 |
Ferritin Quality Control Sample |
234 |
IPV ELISA MAbs Type 1, 2 and 3 (Type 1; No: 234) |
2BADS |
Anti-Brucella Abortus Serum, Bovine (International Standard) |
2CPBETAAT |
Clostridium Perfringens Beta Antitoxin (2nd International Standard) |
2CPEPAT |
Clostridium Perfringens Epsilon Antitoxin (2nd International Standard) |
4024 |
Antisera to SARS CoV-1 S1 Protein (Rabbit) |
520 |
IPV ELISA MAbs Type 1, 2 and 3 (Type 3; No: 520) |
59/015 |
Gas Gangrene (Cl. Perfringens(Cl. Welchii) Type A), Equine |
59/016 |
Corticotrophin (ACTH), Porcine (3rd International Standard) |
59/021 |
Botulinum Antitoxin Equine Type A |
60/001 |
Botulinum Antitoxin Equine Type B |
60/013 |
Tetanus Antitoxin, Equine, for Bioassay |
62/014 |
Lysine Vasopressin, Porcine |
63/005 |
Gas Gangrene Antitoxin (Cl. Histolyticum), Equine |
64/002 |
Rheumatoid Arthritis Serum |
64/014 |
Gas Gangrene Antitoxin (Cl. Septicum), Equine |
64/024 |
Gas Gangrene Antitoxin (Cl. Oedematiens), Equine |
65/093 |
Anti-Thyroglobulin Serum, Human (WHO Reference reagent) |
65/119 |
Renin, Porcine |
65/122 |
Long-acting Thyroid Stimulator, Human |
66/021 |
Tetanus Antitoxin, Equine, for Flocculation Test |
66/138 |
Gastrin II, Porcine |
66/153 |
Diphtheria Antitoxin, Equine |
66/233 |
Anti-Nuclear Factor Serum (Homogenous) Human |
67/037 |
Immunoglobulin D (IgD) Serum, Human |
67/086 |
Immunoglobulins G, A, M Serum Human (International Standard) |
67/099 |
Immunoglobulins G, A & M Serum Human |
67/182 |
Anti-Rubella Serum, Human |
67/183 |
Primary Biliary Cirrhosis Serum, Human |
68/340 |
Anti-Nucleolar Factor Plasma, Human |
68/356 |
Renin, Human (International Standard) |
69/065 |
Autoimmune Antibody to Human Spermatazoa |
69/194 |
Glucagon, Porcine (First International Standard) |
70/302 |
Angiotensin II (25µg) |
71/281 |
Anti-Malaria Plasma P Vivax |
71/326 |
Anti-Malaria Plasma Vivax Ng2 |
72/092 |
Anti-malaria Plasma: Plasmodium falciparum (Ghana) |
72/096 |
Anti-Malaria Serum (P.Malariae) |
72/341 |
Anti-Malaria Plasma P Falciparum |
72/345 |
Anti-Malaria Plasma P Falciparum |
72/348 |
Anti-Malaria Plasma P Vivax |
73/517 |
Anti-D (Rho) Antibodies, Human |
73/545 |
Placental Lactogen, Human (International Reference Preparation) |
73/554 |
Cholera Vaccine (Inaba) |
73/556 |
Cholera Vaccine (Ogawa) |
73/601 |
Carcinoembryonic Antigen (CEA), Human (1st International Reference Preparation) |
74/520 |
Serum Proteins (Other than Immunoglobulins) Human |
74/581 |
Ancrod (1st International Reference Preparation) |
74/586 |
Corticotrophin (ACTH), Porcine (International Working Standard) |
75/506 |
Cocksfoot Pollen Extract |
75/533 |
Chorionic Gonadotrophin, Human, for Radioiodination |
75/535 |
Chorionic Gonadotrophin beta, Human, for Radioiodination |
75/551 |
Chorionic Gonadotrophin beta Subunit, Human (International Reference Preparation) |
75/569 |
Chorionic Gonadotrophin alpha subunit, Human (International Reference Preparation) |
75/595 |
Blood Coagulation Factor Xa, Bovine |
76/508 |
Chorionic Gonadotrophin alpha Subunit, Human, for Radioiodination |
76/515 |
Mannan (Candida Albicans) Purified |
76/522 |
Opacity 5IRP WHO International Standard |
76/525 |
Anti-Birch Pollen Serum, Human |
76/547 |
Influenza anti A/Victoria/3/75 Serum(goat) |
76/575 |
Oxytocin(4th International Standard) |
77/503 |
Anti-Cocksfoot Serum, Human |
77/512 |
Lysine Vasopressin(1st International Standard) |
77/531 |
Influenza anti A/New Jersey/8/76(H1N1) Serum |
77/568 |
Influenza anti B/Hong Kong/8/73 Serum |
77/584 |
Anti-D Pteronyssinus Serum, Human |
77/600 |
Mannan (Candida Albicans) Purified |
77/616 |
Twelve Grass Pollen Extract |
77/643 |
Secretin |
77/662 |
Acarus Siro Extract |
77/664 |
Glycyphagus destructor Extract |
78/517 |
Tyrophagus Putrescentiae Extract |
78/543 |
Kininogenase (Porcine, Pancreatic) (Formerly 1st International Standard) |
78/545 |
Anti-Aspergillus fumigatus Serum, Human |
78/554 |
Luteinizing Hormone, Pituitary, alpha subunit (International Standard) |
78/556 |
Luteinizing Hormone, Pituitary, beta subunit (International standard) |
78/560 |
Influenza Antigen A/Texas/1/77 |
78/569 |
Influenza anti A/Texas/1/77 Serum |
78/575 |
Aspergillus Fumigatus Extract |
78/582 |
Tyrophagus Longior Extract |
78/628 |
Bee Venom |
79/500 |
Parathyroid Hormone, HumanRef. Preparation) |
79/516 |
Influenza anti A/Brazil/11/78 Serum (goat) |
79/552 |
Influenza Antigen A/USSR/92/77 |
79/558 |
Influenza Antigen A/USSR/92/77 |
79/560 |
Influenza Antigen A/Brazil/11/78 |
79/568 |
Influenza Antigen B/Hong Kong/8/73 |
79/572 |
Prekallikrein Activator (PKA), Human |
80/505 |
Growth Hormone, Human, Pituitary. WHO International Standard |
80/517 |
Influenza Antigen A/Bangkok/1/79 |
80/519 |
Influenza Antigen B/Singapore/222/79 |
80/523 |
Influenza anti B/Singapore/222/79 Serum |
80/525 |
Influenza anti A/Bangkok/1/79 Serum |
80/590 |
Tetracosactide. International Ref. Preparation |
81/535 |
Luteinizing Hormone, Human, Pituitary (3rd International Standard) |
81/565 |
Thyroid Stimulating Hormone, Human. WHO International Standard |
82/508 |
Parathyroid Hormone, Human-Type, Synthetic (1-34) fragment |
82/512 |
Parathyroid Hormone, Bovine-Type, Synthetic (1-34) fragment |
82/518 |
Dermatophagoides Pteronyssinus Extract. WHO International Standard |
82/520 |
Timothy Pollen Extract. WHO International Standard |
82/585 |
Anti Poliovirus serum types 1,2 and 3 (3rd International Standard) |
82/587 |
Interferon Gamma (Human, Leukocyte derived) |
82/632 |
Parathyroid Hormone, Bovine. WHO International Standard |
82/652 |
Human Serum Vitamin B12, Pernicous anaemia |
83/501 |
Beta Thromboglobulin, Purified Human. WHO International Standard |
83/505 |
Platelet Factor 4 Human, Purified. WHO International Standard |
83/511 |
Insulin, Bovine. WHO International Standard |
83/514 |
Interferon alpha-1D, (Human rDNA derived) WHO International Standard |
83/515 |
Insulin, Porcine. WHO International Standard |
83/537 |
Influenza Antigen A/Philippines/2/82 |
83/545 |
Influenza anti A/Philippine/2/82 Serum |
83/550 |
Influenza Antigen A/Brazil/11/78 |
83/573 |
Prolactin, Human (4th WHO International Standard.) |
83/575 |
Follicle Stimulating Hormone, Pituitary. WHO International Standard |
84/514 |
Proinsulin, Bovine. International Ref. Preparation |
84/522 |
Birch Pollen Extract. WHO International Standard |
84/528 |
Proinsulin, Porcine. International Ref. Reagent |
84/538 |
Influenza Antigen A/Chile/1/83 |
84/542 |
Influenza Antigen B/Norway/1/84 |
84/581 |
Short Ragweed Pollen Extract. WHO International Standard |
84/614 |
Calcitonin, ASU 1-7 Eel Calcitonin Analogue (Elcatonin) WHO International Standard |
84/628 |
Anti-c Serum, Human |
84/636 |
Influenza anti B/USSR/100/83 Serum |
84/640 |
Influenza anti A/Chile/1/8 Serum |
84/677 |
Influenza anti A/equine/Miami/63 (H3N8) Serum(goat) |
84/685 |
Dog (Canis Familiaris) Hair Dander Extract. WHO International Standard |
85/506 |
C-Reactive Protein, Human. WHO International Standard |
85/516 |
Influenza anti A/Equine/Kentucky/1/81 HA Serum |
85/520 |
Influenza Antigen A/Equine/Kentucky/1/81 |
85/522 |
Thyroid Stimulating Hormone beta subunit |
85/551 |
Anti-Rye Grass Serum, Human |
85/616 |
Haemoglobin F Lysate, Raised. WHO Reference Reagent |
85/669 |
Atrial Natriuretic Factor, Human. WHO International Standard |
86/500 |
Interleukin- 2 (Human, rDNA derived)(2nd International Standard) |
86/536 |
Angiotensin I Human Type Synthetic |
86/538 |
Angiotensin II (2.5µg) |
86/552 |
Interleukin-1 Beta (Human, rDNA derived) |
86/576 |
Influenza Antigen A/Mississippi/1/85 |
86/590 |
Influenza anti A/Mississippi/1/85 Serum |
86/592 |
Influenza anti B/Ann Arbor/1/86/HA Serum |
86/630 |
Influenza Antigen B/Ann Arbor/ 1/86 |
86/632 |
Interleukin-1 alpha (Human rDNA derived) WHO International Standard |
86/678 |
Interleukin-1 alpha (Human, rDNA derived) |
86/680 |
Interleukin-1 beta (Human, rDNA derived) WHO International Standard |
86/690 |
Inhibin, Porcine WHO International Standard |
87/510 |
Influenza Antigen A/Equine/Miami/63 |
87/578 |
Influenza anti A/Leningrad/360/86 Serum |
87/584 |
Influenza Antigen A/Leningrad/360/86 |
87/586 |
Interferon Gamma (Human, rDNA derived) |
87/640 |
Tumour Necrosis Factor beta (Human, rDNA derived) WHO Reference Reagent |
87/654 |
Anti-Ferritin Monoclonal Antibody (1) |
87/662 |
Anti-Ferritin Monoclonal Antibody (2) |
87/714 |
Influenza Antigen A/Sichuan/2/87 |
87/774 |
Influenza Antigen B/Victoria/2/87 |
88/522 |
Bordetella pertussis (Whole cell vaccine) 3BRP |
88/532 |
Tumour Necrosis Factor alpha (Mouse, rDNA derived) |
88/554 |
Influenza Antigen B/Beijing/1/87 |
88/556 |
Calcitonin, Eel WHO International Standard |
88/638 |
Thyroxine-binding globulin. WHO International Standard |
88/646 |
Granulocyte Macrophage Colony Stimulating Factor (Human, rDNA derived) WHO International Standard |
88/654 |
Influenza Antigen A/England/427/88 |
88/656 |
Interleukin-4 (Human, rDNA derived) WHO International Standard |
88/672 |
Influenza anti A/Sichuan/2/87 Serum |
88/678 |
Influenza anti B/Beijing/1/87 Serum |
88/846 |
Influenza anti A/England/427/88 Serum |
89/512 |
Macrophage Colony Stimulating Factor (CSF-1) (Human rDNA derived) WHO International Standard |
89/514 |
Transforming Growth Factor beta-1 (Human, rDNA derived) |
89/516 |
Transforming Growth Factor beta-1 (Bovine) |
89/518 |
Transforming Growth Factor beta-2 (Bovine) |
89/520 |
Interleukin-8 (Human, rDNA derived) WHO International Standard |
89/530 |
Anti-Bordetella pertussis serum (Human) |
89/544 |
Renin, Human, rec DNA |
89/548 |
Interleukin-6 (Human, rDNA derived) WHO International Standard |
89/568 |
Influenza Antigen A/OMS/5389/88 |
89/594 |
Bordetella pertussis (W28) LPS 2ug |
89/596 |
Bordetella pertussis anti-agglutinogen 1(rabbit) |
89/598 |
Bordetella pertussis anti-agglutinogen 2 (rabbit) |
89/600 |
Bordetella pertussis anti-agglutinogen 3 (rabbit) |
89/620 |
Calcitonin, Human. WHO International Standard |
89/666 |
Haemoglobin A2 Lysate, Raised. WHO Reference Reagent |
89/670 |
Bordetella pertussis (W28) LPS25ug |
90/500 |
Influenza Antigen A/Shanghai/16/89 |
90/502 |
Influenza Antigen A/Guizhou/54/89 |
90/504 |
Influenza anti A/Guangdong/39/89 Serum |
90/520 |
Bordetella pertussis, filamentous haemagglutinin (FHA) |
90/530 |
Interleukin-7 (Human, rDNA derived) WHO Reference Reagent |
90/534 |
Mumps Vaccine (Live) WHO Reference Reagent |
90/586 |
Interleukin-5 (Human, rDNA derived) WHO Reference Reagent |
90/636 |
HIV-1 P24 Antigen WHO International Standard |
90/690 |
Anti-Varicella-Zoster Antibody |
90/696 |
Transforming Growth Factor beta-2, Human, rec DNA |
90/712 |
Basic Fibroblast Growth Factor (Human, rDNA derived) WHO International Standard |
90/784 |
Influenza Virus infectious NIB-26 (H3N2) |
91/510 |
Interleukin-3 (Human, rDNA derived) WHO International Standard |
91/530 |
Epidermal Growth Factor (Human, rDNA derived) WHO International Standard |
91/550 |
Epidermal Growth Factor (1-52) (Human, rDNA derived) WHO Reference Reagent |
91/554 |
Insulin-like growth Factor 1 WHO International Standard |
91/612 |
Influenza anti A/Taiwan/1/86 Serum |
91/624 |
Recombinant Human Inhibin |
91/626 |
Activin A, Human, Recombinant. WHO Reference Reagent |
91/656 |
Interleukin-4 (Mouse, rDNA derived) |
91/658 |
Granulocyte Macrophage Colony Stimulating Factor (Mouse rDNA derived) |
91/662 |
Interleukin-3 (Mouse, rDNA derived) |
91/670 |
Influenza Virus infectious NIB-27 (H1N1) |
91/678 |
Interleukin-9 (Human,rDNA derived) WHO Reference Reagent |
91/682 |
Stem Cell Factor (Human rDNA derived) WHO Reference Reagent |
91/688 |
Rubella Vaccine (Live) 1st International Reference Reagent |
92/510 |
Follicle Stimulating Hormone, Human, recombinant. (WHO International Standard) |
92/512 |
Follicle Stimulating Hormone, urofollitropin Human Urinary WHO International Standard |
92/518 |
Macrophage Inflammatory Protein-1 alpha (Human, rDNA derived) |
92/520 |
Rantes (Human, rDNA derived) |
92/530 |
Influenza Antigen A/Texas/36/91 |
92/582 |
Influenza anti B/Yamagata/16/88 Serum |
92/628 |
Influenza Antigen B/Yamagata/16/88 |
92/632 |
Influenza anti A/Beijing/352/89 (H3N2) Serum |
92/644 |
Interleukin-1 Receptor Antagonist (IL-1ra) (Human, rDNA derived) |
92/648 |
Measles Vaccine (Live) 2nd International Reference Reagent |
92/654 |
Plasminogen Activator Inhibitor-1 (PAI-1), plasma Human WHO International Standard |
92/658 |
Papain preparation for use with Anti-D preparation 91/562 |
92/680 |
Serum amyloid A protein. WHO International Standard |
92/734 |
Influenza Virus infectious A/Beijing/32/92 (H3N2) |
92/738 |
Influenza Virus infectious A/Shanghai/24/90 |
92/788 |
Interleukin-11 (Human, rDNA derived) WHO Reference Reagent |
92/794 |
Monocyte Chemoattractant Protein-1 (Human,rDNA derived) |
93/500 |
Influenza Antigen A/Beijing/32/92 |
93/516 |
Influenza Antigen A/Shanghai/24/90 |
93/518 |
Influenza anti A/Beijing/32/92 (H3N2) Serum |
93/522 |
Influenza anti A/Shanghai/24/90 (H3N2) Serum |
93/556 |
Nerve Growth Factor (Human, rDNA derived) WHO Reference Reagent |
93/560 |
Insulin-like growth Factor Binding Protein-3 |
93/562 |
Leukaemia Inhibitory Factor (Human, rDNA derived) WHO Reference Reagent |
93/564 |
Oncostatin M (Human, rDNA derived) WHO Reference Reagent |
93/566 |
Interleukin-2 (Mouse, rDNA derived) |
93/568 |
Influenza Virus infectious A/Beijing/359/89 (H3N2) |
93/574 |
Bone morphogenetic Protein-2 (Human, rDNA derived) WHO Reference Reagent |
93/668 |
Interleukin-1 beta (Mouse, rDNA derived) |
93/672 |
Interleukin-1 alpha (Mouse, rDNA derived) |
93/692 |
Influenza Virus infectious B/Panama/45/90 |
93/722 |
Interleukin-10 (Human rDNA derived) WHO Reference Reagent |
93/730 |
Interleukin-6 (Mouse, rDNA derived) |
93/740 |
Interleukin-7 (Mouse, rDNA derived) |
93/816 |
Influenza Virus infectious A/Harbin/15/92 (H3N2) |
94/500 |
Influenza Antigen B/Panama/45/90 |
94/504 |
Influenza anti A/Shanghai/9/93 Serum |
94/516 |
Influenza Antigen A/Shangdong/9/93 |
94/520 |
Influenza anti B/Panama/45/90 Serum |
94/532 |
Pertussis Vaccine (Whole Cell) WHO International Standard |
94/622 |
Interleukin-13 (Human, rDNA derived) WHO Reference Reagent |
94/674 |
Thyroid Stimulating Hormone, Human recombinant WHO Reference Reagent |
94/684 |
Ciliary Neurotrophic Factor (Human, rDNA derived) WHO Reference Reagent |
94/718 |
Staphylokinase, rec (STAR) |
94/728 |
Platelet-derived Growth Factor-BB (Human, rDNA derived) WHO International Standard |
94/730 |
Tissue Plasminogen Activator (tPA) Antigen in Plasma WHO International Standard |
94/754 |
Interferon Omega (Human, rDNA derived) WHO International Standard |
94/762 |
Influenza Virus infectious RESVIR-8 (H3N2) |
94/766 |
Influenza Virus infectious NIB-34 (H3N2) |
94/784 |
Interferon alpha (Human, leukocyte derived)WHO International Standard |
94/786 |
Interferon alpha Concensus Sequence (Human rDNA derived) WHO International Standard |
94/790 |
MAPREC analysis of Poliovirus type 3 (Sabin). Synthetic DNA 100% 472-C WHO International Standard |
95/510 |
Influenza Antigen A/Texas/36/91 |
95/516 |
Influenza Antigen A/Johannesburg/33/94 |
95/522 |
Anti-HBc (Anti-hepatitis B core antigen) WHO International Standard |
95/524 |
Influenza anti A/Johannesburg/33/94 Serum |
95/528 |
Folate, Whole Blood Haemolysate WHO International Standard |
95/542 |
MAPREC analysis of Poliovirus type 3 (Sabin) Synthetic DNA 0.9% 472-C WHO International Standard |
95/544 |
Interleukin-12 (Human, rDNA derived) WHO Reference Reagent |
95/554 |
Interleukin-15 (Human, rDNA derived) WHO Reference Reagent |
95/564 |
Single Chain Urinary-Type Plasminogen Activator (SCuPA), (Non-Glyc) |
95/568 |
Interferon Alpha n1 (Human lymphoblastoid cell derived) WHO International Standard |
95/572 |
Interferon alpha-1/8 (Human, rDNA derived) WHO International Standard |
95/574 |
Interferon Alpha n3 (Human, leukocyte derived) WHO International Standard |
95/580 |
Interferon alpha-2c (Human, rDNA derived) WHO International Standard |
95/646 |
Parathyroid Hormone 1-84, human, recombinant (1st International Standard) |
95/650 |
Interferon alpha-2a (Human, rDNA derived) WHO International Standard |
95/656 |
Interferon alpha 2b (Human rDNA derived)(3rd International Standard) |
95/668 |
Single Chain Urinary-Type Plasminogen Activator (SCuPA), (Glyc) |
95/674 |
Anti-Meningococcal Serogroup A mAb |
95/678 |
Anti-Meningococcal Serogroup C mAb |
96/528 |
Soluble Tumour Necrosis Factor Receptor Type 1, (Human, rDNA derived) |
96/532 |
FMS-like tyrosine kinase 3 ligand (Human, rDNA derived) WHO Reference Reagent |
96/534 |
Brain-derived Neurotrophic Factor (Human, rDNA derived) WHO Reference Reagent |
96/538 |
Insulin-like growth Factor-II (Human rDNA derived) WHO Reference Reagent |
96/556 |
Hepatocyte Growth Factor/Scatter Factor (precursor), (Human rDNA derived) WHO International Standard |
96/564 |
Hepatocyte Growth Factor/Scatter Factor (Human, rDNA derived) WHO Reference Reagent |
96/572 |
MAPREC analysis of Poliovirus type 3 (Sabin) Low virus reference 0.7%472-C WHO Reference Reagent |
96/578 |
MAPREC analysis of Poliovirus type 3 (Sabin) High virus reference 1.1%472-C WHO Reference Reagent |
96/602 |
Luteinizing Hormone, Human, recombinant WHO International Standard |
96/784 |
Inhibin B, Human WHO Reference Reagent |
96/836 |
Influenza Virus infectious RESVIR-9 (H3N2) |
96/850 |
Influenza Virus infectious NIB-39 (H1N1) |
97/518 |
Influenza Antigen A/Johannesburg/82/96 |
97/538 |
Anti-Granulocyte Macrophage Colony Stimulating Factor Serum |
97/550 |
Islet Cell Antibodies WHO Reference Reagent |
97/558 |
Bordetella pertussis anti 69kD serum (sheep) |
97/562 |
Blood Coagulation Factors IXa Concentrate, Human, recombinant(1st I.S.) |
97/564 |
Bordetella pertussis anti FHA serum (sheep) |
97/572 |
Bordetella pertussis PT anti serum (sheep) |
97/574 |
Bordetella pertussis anti Fim3 serum (sheep) |
97/584 |
Influenza Antigen A/Equine/Newmarket/2/93 |
97/594 |
Leptin, Human, Recombinant WHO International Standard |
97/596 |
Influenza Antigen A/Equine/Newmarket/1/93 |
97/600 |
Interleukin-2 Soluble Receptor (human, rDNA derived) |
97/610 |
Influenza anti A/equine/Newmarket/1/93 Serum |
97/612 |
Influenza anti- A/Nanchang/933/95 (H3N2) HA serum |
97/614 |
Influenza anti A/Equine/Newmarket/2/93 (H3N8) HA Serum (SH-376) |
97/626 |
Leptin, Mouse, Recombinant WHO International Standard |
97/642 |
Bordetella pertussis anti serum (mouse) 1RR |
97/646 |
Anti-Hepatitis A Immunoglobulin, Human (W1041) WHO International Standard |
97/648 |
Anti-Measles serum (3rd International Standard) |
97/692 |
Influenza Virus infectious IVR-108 (H3N2) |
97/714 |
Prolactin, Human, recombinant. WHO Reference Reagent |
97/722 |
Influenza Virus infectious A/duck/Sing-Q/119/97 (H5N3) |
97/748 |
Influenza Antigen B/Harbin/7/94 |
97/756 |
MAPREC analysis of Poliovirus type 2 (Sabin), low virus reference 0.65%481-G. WHO Reference Reagent |
97/758 |
MAPREC analysis of Poliovirus type 2 (Sabin) Synthetic DNA 0.67%481-G WHO International Standard |
97/760 |
Influenza Antigen A/Beijing/262/95 |
98/524 |
MAPREC analysis of Poliovirus type 2 (Sabin) Synthetic DNA, 100%481-G WHO International Standard |
98/544 |
Influenza Virus infectious RESVIR-13 (H3N2) |
98/572 |
Diphtheria and Tetanus Antitoxin, Guinea Pig Serum |
98/574 |
Somatropin WHO International Standard |
98/580 |
Prolactin Human, recombinant, glycosylated WHO Reference Reagent |
98/582 |
Prolactin, Human, recombinant, non-glycosylated WHO Reference Reagent |
98/586 |
Calcitonin, Salmon. WHO International Standard |
98/596 |
MAPREC analysis of Poliovirus type 2 (Sabin), high virus reference 1.21% 481-G. WHO Reference Reagent |
98/600 |
Influenza Virus infectious NIB-40 (H5N3) |
98/604 |
Influenza anti B/Harbin/7/94/HA Serum |
98/610 |
Influenza Virus infectious ARIV-1 (H5N3) |
98/666 |
Influenza anti A/Hong Kong/489/97 (H5N1) Serum (sheep) |
98/686 |
Negative Control Guinea Pig Serum (Diphtheria and Tetanus Serology) |
98/708 |
Haemiglobincyanide WHO International Standard |
98/714 |
Tissue Plasminogen Activator, Human, Recombinant WHO International Standard |
98/718 |
Neurotrophin 3 |
98/762 |
Influenza Virus infectious Resvir-14 (H3N2) |
98/772 |
Influenza anti A/Beijing/262/95 Serum |
98/774 |
Influenza Antigen B/Shangdong/7/97 |
98/778 |
Influenza Virus infectious A/Sichuan/346/98 (H3N2) |
99/506 |
Anti-PT S1 subunit Monoclonal Antibody (1B7) |
99/508 |
Anti-PT S1 subunit Monoclonal Antibody (1D7) |
99/510 |
Anti-PT S1 subunit Monoclonal Antibody (3F11) |
99/512 |
Anti-PT S1 subunit Monoclonal Antibody (10D6) |
99/514 |
Anti-PT S1 subunit Monoclonal Antibody (8G4) |
99/516 |
Anti-PT S1 subunit Monoclonal Antibody (E1E) |
99/518 |
Anti-PT S1 subunit Monoclonal Antibody (E2E) |
99/520 |
Anti-PT S1 subunit Monoclonal Antibody (3F10) |
99/522 |
Anti-PT S1 subunit Monoclonal Antibody (11D9) |
99/524 |
Anti-PT S1 subunit Monoclonal Antibody (4D10) |
99/526 |
Anti-PT S23 subunit Monoclonal Antibody (11E6) |
99/528 |
Anti-PT S23 subunit Monoclonal Antibody (10C9) |
99/530 |
Anti-PT S23 subunit Monoclonal Antibody (10B5) |
99/532 |
Anti-PT S23 subunit Monoclonal Antibody (G9A) |
99/534 |
Anti-PT S23 subunit Monoclonal Antibody (3F6) |
99/536 |
Anti-PT S2 subunit Monoclonal Antibody (3A12) |
99/538 |
Anti-PT S2 subunit Monoclonal Antibody (2H3) |
99/540 |
Anti-PT S2 subunit Monoclonal Antibody (9G8) |
99/542 |
Anti-PT S3 subunit Monoclonal Antibody (7E10) |
99/544 |
Anti-PT S3 subunit Monoclonal Antibody (7G11) |
99/546 |
Anti-PT S3 subunit Monoclonal Antibody (4G5) |
99/548 |
Anti-PT S3 subunit Monoclonal Antibody (2E12) |
99/550 |
Anti-PT S3 subunit Monoclonal Antibody (6F8) |
99/552 |
Anti-PT S3 subunit Monoclonal Antibody (10B8) |
99/554 |
Anti-PT S4 subunit Monoclonal Antibody (7F2) |
99/556 |
Anti-PT S4 subunit Monoclonal Antibody (6B3) |
99/558 |
Anti-PT S4 subunit Monoclonal Antibody (6G8) |
99/560 |
Anti-PT S4 subunit Monoclonal Antibody (9F3) |
99/562 |
Anti-PT S4 subunit Monoclonal Antibody (1H2) |
99/564 |
Anti-PT S4 subunit Monoclonal Antibody (9C6) |
99/566 |
Anti-PT S4 subunit Monoclonal Antibody (6D6) |
99/568 |
Anti-PT S5 subunit Monoclonal Antibody (7E3) |
99/570 |
Anti Filamentous Haemagglutinin Monoclonal Antibody (1C6) |
99/572 |
Anti-Filamentous Haemagglutinin Monoclonal Antibody (2E9) |
99/574 |
Anti Filamentous Haemagglutinin Monoclonal Antibody (12G10) |
99/586 |
Influenza Antigen B/Yamanashi/166/98 |
99/614 |
Influenza Antigen A/Sydney/5/97 |
99/616 |
Yellow Fever Vaccine. WHO International Standard |
99/624 |
Influenza Antigen A/Sydney/5/97 |
99/642 |
Chorionic Gonadotrophin, nicked, human. WHO Reference Reagent |
99/650 |
Chorionic Gonadotrophin, beta subunit, human. WHO Reference Reagent |
99/666 |
Anti-HPA-5b (Minimum Potency) WHO Reference Reagent |
99/674 |
HIV-2 (antibody) Monitor Sample |
99/688 |
Chorionic Gonadatrophin, intact, Human. WHO Reference Reagent |
99/692 |
Chorionic Gonadotrophin, nicked beta subunit, Human WHO Reference Reagent |
99/706 |
Anti-Meningococcal human reference serum CDC1992 |
99/708 |
Chorionic Gonadatrophin, beta core fragment, Human WHO Reference Reagent |
99/710 |
Anti-HIV 1 (1 in 5 BWS) |
99/714 |
Influenza Antigen A/Singapore/1/57 (H2N2) |
99/720 |
Chorionic Gonadotrophin, alpha subunit, Human (purified) |
99/750 |
British Working Standard for Anti-HIV 1 |
99/824 |
Influenza Virus infectious RESVIR 16 (H3N2) |
99/828 |
Influenza Antigen B/Yamanashi/166/98 |
99/836 |
Anti-D Minimum Potency Standard for blood grouping reagents WHO International Standard |
AFP |
Alpha-Foetoprotein. WHO International Standard |
BUSB |
Botulinum Antitoxin Equine Type B. WHO International Standard |
CDS |
Anti-Canine Distemper Serum. WHO International Standard |
CHAN |
Cholera Antitoxin, Goat. WHO International Standard |
CHS |
Anti-Canine Hepatitis Serum |
COT |
Clostridium novyi (alpha) Toxoid. WHO Reference Reagent |
CWBETATD |
Clostridium Welchii (Perfringens)(Beta) Toxoid CwBT WHO Reference Reagent |
CWEPSILTD |
Clostridium Welchii (Perfringens) (Epsilon) toxoid |
DY |
Anti-Dysentery (shiga) serum, Equine. WHO International Standard |
HBOHA |
Lyophilised HBO-HA Antigen for ELISA, Lot 17 |
JNIH-11 |
Bordetella pertussis anti FHA serum (mouse) |
JNIH-12 |
Bordetella pertussis PT( LPF) anti serum, (mouse) |
JNIH-3 |
Acellular Pertussis Vaccine - 1st IS. |
JNIH-4 |
Bordetella pertussis filamentous haemagglutinin (FHA) |
MEF/001 |
Primary Mouse Embryo Fibroblasts (p0) |
MGDS |
Anti-Mycoplasma gallisepticum Serum. WHO Reference Reagent |
NDS |
Anti-Newcastle Disease Serum. WHO International Standard |
NVIA |
Newcastle Disease Vaccine (Inactivated) WHO International Standard |
OE |
Gas Gangrene Antitoxin (Cl. novyi), Equine WHO International Standard |
PE |
Gas Gangrene Antitoxin (Cl. Perfringens alpha antitoxin) Equine WHO International Standard |
PPDA |
Purified Protein Derivative (PPD) of M Avium Tuberculin WHO International Standard |
PPDBOV |
Purified Protein Derivative (PPD) of Mycobacterium bovis Tuberculin (WHO 1st International Standard) |
PPDT |
Purified Protein Derivative (PPD) of M. Tuberculosis Tuberculin WHO International Standard |
QF |
Anti-Q Fever Serum, Bovine WHO International Standard |
RBT/16 |
Thromboplastin, Rabbit, Plain 5th International Standard 2016. |
RTF/16 |
Thromboplastin, Human, Recombinant, Plain 5th International Standard 2016. |
RUBI-1-94 |
Anti-rubella Immunoglobulin, Human WHO International Standard |
SES |
Swine Erysipelas Serum (anti-N) WHO Reference Reagent |
SFS |
Anti-Swine Fever Serum WHO International Standard |
SMV |
Smallpox Vaccine WHO International Standard |
SPDS-S2 |
Anti-Salmonella Pullorum Serum (Std. Form S) WHO International Standard |
SPDS-V |
Anti-Salmonella Pullorum Serum (Variant Form V) WHO International Standard |
SPLS |
Anti-Staphylococcal P-V Leucocidin serum, Equine WHO Reference Reagent |
SS-319/20 |
FITC CD4 Positive Control Cells |
SSCLOT5 |
SSC Secondary Coagulation Standard Lot#5 |
STA |
Staphylococcus Alpha Antitoxin, Equine WHO International Standard |
STT |
Diphtheria (Schick) Test Toxin WHO International Standard |
TILI |
Anti-tick borne encephalitis serum (Louping Ill) WHO International Standard |
TISA |
Anti-tick borne encephalitis serum (Sophyn & Absettarov) WHO International Standard |
TYVK |
Typhoid Vaccine (acetone-inactivated) WHO International Standard |
TYVL |
Typhoid Vaccine (heat-phenol-inactivated) WHO International Standard |
VI |
Gas Gangrene Antitoxin (Cl. Septicum), Equine WHO International Standard |
W1004 |
Anti-C complete blood typing serum,human WHO International Standard |
W1005 |
Anti-E complete blood typing serum, human WHO International Standard |
W1007 |
Anti-c Incomplete blood typing serum, human WHO International Standard |
W1044 |
Anti-Varicella zoster immunoglobulin WHO International Standard |
W1062 |
Anti smooth muscle(anti actin) autoantibody. WHO Reference Reagent |
W1063 |
Anti nuclear ribonucleoprotein(nRNP) autoantibody WHO Reference Reagent |
W1064 |
Anti-Nuclear factor serum,homogenous(66/233) |
YF |
Anti-Yellow Fever Serum, monkey WHO Reference Reagent |